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GENERAL ABSTRACT 
Infection with Helicobacter pylori has been associated with the pathogenesis of numerous 
stomach and gastroduodenal diseases that pose threats to public health. Eradicaftion of this 
pathogen is a global challenge due to its alarming rate of multidrug resistance. Consequently, 
to find an alternative treatment, the search is increasingly focused on new antimicrobial 
product from natural sources including honey. Honey has been used as medicine in several 
cultures since ancient time due to its enormous biomedical activities. Its beneficial qualities 
have been endorsed to its antimicrobial, antioxidant, anti-inflammatory properties added to its 
phytocomponents. In this study, the anti-H. pylori activity of South African honeys and their 
solvent extracts as well as the phytochemicals present in the two most active honeys were 
evaluated. Agar well diffusion test was used to investigate the antimicrobial activity of six 
honey varieties obtained from different locations in the country. Subsequently, the honeys 
were extracted with four organic solvents viz n-hexane, diethyl ether, chloroform and ethyl 
acetate employed in order of increasing polarity. The antibacterial activity of the different 
solvent extracts of each honey was evaluated by agar well diffusion; broth micro dilution and 
time kill assays. Different chromatographic techniques (Thin layer & column 
chromatography) were employed to enumerate the phytochemical constituents in the most 
active solvent extracts of Pure Honey (PH) and Champagne Royal Train (CRT); and were 
identified by gas-chromatography linked mass-spectrometry. Linalool pure compound was 
equally evaluated for anti-H. pylori activity in a bid to trace the antibacterial agent among the 
variety of compounds identified. Data were analyzed by One-way ANOVA test at 95% 
confidence interval. Crude honeys and their solvent extracts demonstrated potent anti-H. 
pylori activity with zone diameter that ranged from [16.0mm (crude) to 22.2mm (extract)] 
and percentage susceptibilities of  test isolates between 73.3% (crude) and 93.3% (extract). 
The chloroform extracts of PH and CRT were most active with MIC50 in the ranges 0.01-
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10%v/v and 0.625-10%v/v respectively, not significantly different from amoxicillin (P> 
0.05); and efficient bactericidal activity (100% bacterial cells killed) at 1/2MIC and 4xMIC 
over different time intervals, 36-72hrs and 18-72hrs respectively. The appearance of bands on 
the thin layer chromatography (TLC) chromatogram spotted with the chloroform extracts of 
PH and CRT; and developed with hexane: ethyl acetate: acetic acid (HEA) and methanol: 
acetic acid: water (MAAW) solvent systems indicated the presence of compounds. 
Purification of the compounds contained in these extracts over silica gel column yielded 
numerous fractions which were evaluated for antibacterial activity and purity. PHF5 was the 
most active fraction with a mean MIC50 value of 1.25mg/mL. Volatile compounds belonging 
to different known chemical families in honey were identified in all the active fractions 
obtained from PH. Conversely, only four compounds were identified in the active fractions 
obtained from CRT hence the non volatile constituents could be of prime relevance with 
respect to antibacterial activity of this honey. Of novelty was the presence of thiophene and 
N-methyl-D3-azirdine compounds, essential precursors used for the synthesis of natural 
products and pharmaceuticals with vital biomedical properties. Linalool demonstrated potent 
inhibitory (MIC95, 0.002- 0.0313mg/mL) and bactericidal activity (0.0039-0.313mg/mL) 
against the test isolates. On the other hand, a significant difference was recorded (P < 0.05) in 
comparing the activity of linalool compound to the fractions. PH could serve as a good 
economic source of bioactive compounds which could be employed as template for the 
synthesis of novel anti-H. pylori drugs. However, further studies are needed to determine the 
non volatile active ingredients in PH and CRT as well as toxicological testing.  
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CHAPTER ONE 
GENERAL INTRODUCION 
 1.1 INTRODUCTION 
The human gastric pathogen Helicobacter pylori (H. pylori), is a spiral, Gram-negative and 
microaerophilic bacterium that colonizes the stomach of more than 50% of the world’s 
population and can persist for a lifetime if not completely eradicated (Ahmed and Sechi, 
2005). It is one of the most genetically diverse of all bacterial species and has been 
incriminated as the main etiological agent in many diseases of the upper gastrointestinal tract 
(GIT) such as chronic gastritis, gastric and duodenal ulcers and as a risk factor for mucosa-
associated lymphoid tissue lymphoma as well as adenocarcinoma (Appelmelk et al., 2000). 
 
However, majority of the infected patients remain asymptomatic; with only a small subset of 
infected people experiencing H. pylori-associated illnesses, in view of the fact that the 
outcome of infection depends on a variety of bacterial, host genetic and environmental factors 
that mostly relate to the pattern and severity of gastritis (Krusters et al., 2006). Several H. 
pylori virulence genes have been identified, of these, oipA, vacA, cagA and babA appear to 
play a major role in pathogenicity (Yilmaz et al., 2006). 
 
The prevalence of H. pylori shows geographical, age and socio-economic variations, with 
rates ranging from 20% - 50% in developed countries and over 80% in the developing 
countries. In Western countries, H. pylori infection is on a steep decline mainly because of 
the success of combination therapies and improved personal hygiene and community 
sanitation to prevent re-infection (Ahmed and Sechi, 2005). On the other hand, in developing 
countries, infection is usually acquired in childhood and is associated with low socio- 
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economic status, overcrowding, poor sanitation and unclean water supplies (Feldman, 2001; 
Dube et al., 2009a). H. pylori has been reported to be ubiquitous in Africa. Ndip et al. 
(2008a) conducted a study in Cameroon and documented a high prevalence of 92.2%. 
Interestingly, the organism has been reported to be prevalent in South Africa; Samie et al. 
(2007) reported an H. pylori prevalence of 50.6% in their study in Venda, North of the 
country. Equally, Dube et al. (2009b) presented a high prevalence (85.6%) of H. pylori 
antigens in fecal samples obtained from asymptomatic individuals in the Nkonkobe 
municipality, in the Eastern Cape Province of South Africa. Moreover, Tanih et al. (2010) 
reported a prevalence of 66.1% in patients who presented with gastric-related morbidities at 
Livingstone Hospital, Port Elizabeth, in the Eastern Cape Province of the country. 
 
H. pylori is thought to be indigenous to the human population and is well adapted to existing 
in the gastric mucosa, so humans are the major reservoir. While it exists as normal flora in 
some people, in others its causes serious clinical manifestations. In spite of its implications in 
the above-mentioned diseases and its high prevalence rate worldwide, available literature 
states that the mode of its transmission is poorly understood (Suzuki et al., 2008); although, 
person-to-person transmission is suggested either by fecal-to-oral, oral-to-oral and gastric-to-
oral routes (van Duynhoven and de Jonge, 2001; Asrat et al., 2004) in the general population.  
 
Due to the public health importance of H. pylori since its discovery and coupled with its role 
in the pathogenesis of many stomach diseases, effective diagnostic methods are mandatory. 
The available methods could be classified as invasive or non invasive tests (Mégraud and 
Lehours, 2007). Invasive tests are biopsy-based tests, thus require endoscopy and include the 
biopsy urease test, histology, fluorescent in situ hybridization, culture and polymerase chain  
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reaction (PCR) (Liu et al., 2008). To evade endoscopy, non invasive tests such as 13C-urea 
breath tests, serology and stool antigen enzyme immunoassay tests have been used in various 
clinical setting to detect the pathogen (Oderda et al., 2000). These different diagnostic 
procedures employed in the identification of H. pylori are usually associated with different 
degrees of specificity as well as sensitivity.  
 
Strategies to limit the burden of H. pylori infections and its complications are needed, and 
prevention by treatment of H. pylori infection at childhood has been suggested. Conventional 
treament of H. pylori infections is by triple therapy which composes of a PPI plus two 
antibiotics (i.e. clarithromycin or amoxicillin with metronidazole); that has been accepted as 
the first-line treatment of choice (Hardin and Wright, 2002) and administered for 7-14days. 
Eradication of the bacterium from the foregut grades to effective healing of ulcers (Meurer 
and Bower, 2002), prevents ulcer relapse (Ables et al., 2007), reduces recurrence of gastric 
cancer (Lee et al., 2008) and potentially decreases the risk of progression to gastric 
carcinoma (Bytzer and O’Morain, 2005; Ndip et al., 2008a). On the other hand, there are 
shortcomings associated with treatment regimens for the bacterium’s eradication; some of 
which have been presented elsewhere (Manyi-Loh et al., 2010).  
 
These conundrums go beyond finding the correct combination of antibiotics and 
manipulation of gastric pH to ensure eradication and include avoiding the development of 
antimicrobial resistance and ensuring compliance with prescribed treatment (O’Connor et al., 
2009). Accordingly, the standard 7-14 days triple therapies fail to eradicate H. pylori 
infections in up to 20-25% of patients (Fuccio et al., 2007). 
 
 
 4 
 
Many H. pylori strains show resistance to the limited range of antibiotics used in its treatment 
in vitro. Antibiotic resistance of H. pylori strains is prevalent world-wide and varies widely 
by geographic location and socio-economic status (Alarcón et al., 1999). Moreover, H. pylori 
has been reported to develop resistance to clarithromycin, a key antibiotic in the triple 
therapy as well as metronidazole an important antibiotic used in its treatment (Mégraud, 
2004).  The prevalence of such resistant strains is highest in the developing countries. In 
South Africa, Tanih et al. (2010a) documented a resistance rate of 95.5% for metronidazole 
among the isolates circulating in the Eastern Cape Province. In addition, there is emerging 
resistance of the bacterium to tetracycline, fluoroquinolones, and rifampicins, which are 
alternative antibiotics with known anti-H.pylori activity (Mégraud, 2004).   
 
Therefore, there is the need to seek alternative compounds from other sources with proven 
antimicrobial activity. This has led to the search of active antibacterial agents from natural 
products, with the aim of discovering potentially useful active ingredients that can serve as 
source and template for the synthesis of new antimicrobial drugs (Aibinu et al., 2002). 
Several authors have documented the anti-H. pylori activity of different natural products; 
plants (Zhang et al., 2005; Zeyrek and Oguz, 2005; Ndip et al., 2008b; Zaidi et al., 2009;), 
probiotics (Lesbros-Pantoflickova et al., 2007) and honey (Nzeako and Al-Namaani, 2006; 
Ndip et al., 2007). 
 
More recently, there is renaissance of interest in the use of honey for treatment of microbial 
infections and it constitutes a potential source of new compounds that may be useful in the 
management of H. pylori infections (Manyi-Loh et al., 2010).  Honey is the natural sweet 
substance produced by honeybees from plant nectar, plant secretions and from excretions of 
plant sucking insects (aphids) (Williams et al., 2009). It has been consumed since ancient 
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times as a high nutritive value food distinguished by its characteristic aroma and pleasant 
sweet taste. The antimicrobial potential of honey has been endorsed to its high osmolarity, 
low acidity, hydrogen peroxide content as well as non-peroxide components.  
 
Notwithstanding, hydrogen peroxide is the major antibacterial factor in honey, produced by 
glucose oxidase enzyme from the oxidation of glucose in the presence of water (French et al., 
2005). On the other hand, the non-peroxide components (phytochemicals) which are derived 
from plant or bee constitute of flavonoids, non flavonoid phenolic compounds and volatiles. 
Volatile organic compounds in honey originate from numerous biosynthetic pathways  
(Guyot-Declerck et al., 2002) and could be classified as hydrocarbons, alcohols, aldehydes, 
ketones, acids, norisoprenoids, benzene derivatives, terpenes and its derivatives, furan and 
pyran derivatives (Barra et al., 2010).  
 
Ndip et al. (2007) documented the anti-H. pylori activity of four honey varieties (Mountain, 
Manuka™,Capillano®, Eco-honey) obtained from different geographical locations. The 
strongest inhibitory activity was demonstrated by Mountain honey with MIC and MBC 
concentrations in the ranges 0.117 - 0.938μg/mL and 0.366 - 2.965μg/mL respectively. This 
preliminary study confirmed the use of these honeys in folk medicine and provides the basis 
for a more detailed evaluation. 
 
 However, it is evident that honeys obtained from different floral sources, different regions 
and countries vary in their antimicrobial potency due to differences in their chemical 
composition which is greatly influenced by the prevailing climatic conditions and soil 
characteristics in the different geographical areas (Castro-Várquez et al., 2010). So, plant  
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originated bioactive components can be transferred to honey by the foraging bees 
(Baltrusaitytė et al., 2007). Even honeys obtained from the same floral source but in different 
geographical locations have shown variation in their chemical composition therefore, could 
influence their antimicrobial activity. Undoubtedly, the chemical composition of honey 
depends on the floral source used to collect nectar, seasonal and environmental factors, as 
well as processing and storage conditions (Yao et al., 2003). 
 
As a result, a survey of honey varieties obtained from the vast floral biodiversity in South 
Africa, might unearth a honey with good antibacterial activity against this medically 
important pathogen. Against this background, the present study sought to evaluate the 
antibacterial and phytochemical properties of selected South African honeys including Pure 
Honey (PH), Champagne Royal Train (CRT), Goldcrest (GC), Citrus Blossom (CB), 
Honeyleine (HL) and Heritage (HH) on clinical isolates of H. pylori obtained from patients 
with gastric related pathologies attending Livingstone Hospital, Port Elizabeth, in the Eastern 
Cape Province of South Africa. 
 
1.2 Rationale 
H. pylori infection is one of the most chronic bacterial infections of mankind (Ndip et al., 
2004). Several studies have related a high prevalence of this pathogen to low socio-economic 
status, a situation common in the Eastern Cape Province in particular and other areas of the 
country in general.  Its infections have been shown to have a high incidence in South Africa, 
being present in both asymptomatic and symptomatic individuals, as expected in developing 
countries (Dube et al., 2009b; Tanih et al., 2010a). Unsucccessful eradication of the pathogen 
(failure rates between 10 & 25%) (Suerbaum and Michetti, 2002) as well as increase in its 
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resistance to antibiotics implemented in the triple therapy is a public health issue of global, 
national and local dimension.  
 
Furthermore, undesirable side effects of the drugs, poor patient compliance and the 
significant cost of combination therapy are added challenges. Also, some of the key 
antibiotics are at times not readily available in rural areas thus in addition compounding the 
problems for patients. Moreover,  immunization of individuals which could be the best 
method of prevention of this infection at childhood, the age at which most infections start is 
still pending. These challenges  associated with significant levels of treatment failure and 
contraindications for some patients therefore, require the exclusive need to search alternative 
approaches of eradicating or preventing H. pylori infections (O’Gara et al., 2000). 
 
 Phytomedicine has proven to be an unexploited treasure for the discovery of model 
compounds to cure different diseases including gastrointestinal (GI) disorders (Thompson 
and Ernst, 2002). This has led to the re-evaluation of the therapeutic use of ancient remedies, 
such as plants and plant-based products including honey. At present, a number of honeys are 
sold with standardized levels of antibacterial activity. For instance, Manuka and Capillano 
produced in Australia are sold as therapeutic honeys suitable for use in ulcers, infected 
wounds and burns (Lusby et al., 2005).  
 
Therefore, the search for other honeys with antimicrobial activity from different regions and 
countries continues. The observation that honey in New Zealand and Saudi Arabia at 
concentrations approximating 20% v/v can inhibit the growth of H. pylori in vitro and the 
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finding that Medihoney and Manuka honeys have been shown to have in vivo activity and are 
suitable for use in ulcers, infected wounds and burns are important findings (Lusby et al., 
2005), which could be exploited clinically. 
 
Consequently, several studies have been focused on the anti-H. pylori activity of honey  and 
their solvent extracts  in different parts of the world (Ndip et al., 2007; Nzeako and Al-
Namaani, 2006). Nonetheless, to the best of my knowledge there is no existing data in the 
literature on the antibacterial activity of honey on clinical isolates of H. pylori circulating in 
South Africa, more especially since this organism and its antibiotic resistant strains have been 
reported to be prevalent in the country (Mosane et al., 2004; Samie et al., 2007; Tanih et al., 
2010b).  According to Pubmed there is no evidence of such study. 
 
Owing to the fact that the pathogen exhibits profound heterogeneity and that variation occurs 
in the antimicrobial activity of honey obtained from different regions and countries (Basson 
and Grobler, 2008; Manyi-Loh et al., 2010), it becomes necessary to evaluate the 
antibacterial activity of  selected honeys and their solvent extracts  on clinical isolates of H. 
pylori circulating in South Africa in an attempt to identify new lead molecules, which could 
be used in the development of new drugs against the pathogen to circumvent the problem of 
increasing drug resistance. These new organic molecules with antibacterial activity, which 
could be inexpensive and readily available to the local population would therefore lead to an 
improvement in primary health care.   
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1.3 Hypothesis 
Honey can provide potent and affordable antibacterial agents for the treatment of H. pylori 
infections. 
1.4 Objectives 
1.4.1 Overall objective 
         To validate scientifically the use of  honey  in folk  medicine.   
1.4.2 Specific objectives 
i) To screen the honey varieties for anti-H. pylori activity. 
ii) To extract the components responsible for this activity. 
iii) To determine the Minimum Inhibitory Concentration (MIC) of honey extracts 
displaying anti-Helicobacter activity. 
iv) To ascertain the rate of kill of these active honey extracts. 
v) To isolate and purify the active compounds from the selected honey extracts. 
vi) To determine the volatile constituents in the active fractions of selected honey 
extracts. 
vii) To identify the volatile compounds responsible for anti-H. pylori activity in the most 
active solvent extracts. 
 
      1.5 Chapter overviews 
This thesis comprises of six chapters. Chapter one represents a general introduction to the 
topic of the thesis. 
Chapter two; literature review. It encompasses materials on the physiology and growth 
conditions of H. pylori, its genes and genomes, pathogenesis and clinical manifestations, 
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diagnosis of H. pylori infections, epidemiology, and treatment (conventional), factors 
implicated in treatment failure, antimicrobial resistance, prospective natural remedies and 
an overview of honey as an alternative source of treatment for H. pylori infections. 
 
Chapter three covers the general antibacterial activity (inhibitory) of all the honeys 
studied and their solvent extracts. Pure Honey (PH), Citrus Blossom (CB) and Goldcrest 
(GC) honeys were most active at 75% v/v concentration whilst Champagne Royal Train 
(CRT), Heritage Honey (HH) and Honeyleine (HL) honeys were most active at 50% v/v 
concentration. The four most active honeys i.e. PH, GC, CRT & HL were subjected to 
solvent extraction and the resulting solvent extracts were equally evaluated for their anti-
H. pylori activity.  
 
Chapter four focuses on the bactericidal activity (time kill assay) of the most active 
solvent extract of PH, GC, CRT and HL honeys that were prevoiusly reported as the most 
active honeys. These included the chloroform extract of PH, n-hexane extract of GC, 
chloroform extract of CRT and the ethyl acetate extract of HL. 
 
Chapter five contains materials on the phytochemical studies of the chloroform extract of 
the two most active honeys at different concentrations (i.e. PH at 75% v/v and CRT at 
50%v/v concentration) via thin layer chromatography, column chromatography and 
identification of volatile compounds by gas chromatography linked mass spectrometry. 
However, each of the above–mentioned chapters has its own introduction, materials and 
methods, results, discussion, conclusions and references. The chapters were arranged in 
accordance with the order of the bioassays. 
Chapter six assembles the general discussion, conclusions and recommendations. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Physiology and growth conditions of H. pylori 
In 1984, Marshall and Warren isolated a curved bacterium from the stomach of patients with 
gastritis and peptic ulcer and classified it under the genus Campylobacter. Later, this 
bacterium was placed under the genus Helicobacter due to differences in flagellation, cell 
wall composition and antimicrobial susceptibility, presence of sheath, urease enzyme and 
bulb as well as formation of glycocalyx in vitro (Velázquez and Feirtag, 1999). 
 
H. pylori is a Gram-negative, S-shaped or curved rod-like bacterium with 1 to 3 turns, 0.5 x 
5µm in length, with a tuft of 5 to 7 polar sheathed flagella. However, the bacterium could 
exist in coccoid forms owing to prolonged incubation or adaptation to marginal or hostile 
environment (Andersen et al., 1997). The response to altered environment leads to a change 
in morphology, metabolism and growth behaviour. Coccoid forms have been implicated as 
possible reservoirs of bacteria exposed to harsh conditions and may be involved in 
transmission of infection or as in vivo cells could be responsible for treatment failures 
(Worku et al., 1999).  
 
Coccoid forms of H. pylori are viable but non-culturable and can revert to the spiral 
morphology and re-grow once an appropriate environment is encountered (Shirai et al., 
2000). Generally, it is considered that the spiral morphology and flagella are essential for 
colonization of gastric and intestinal mucus as well as for pathology. In addition, H. pylori is 
a fastidious micro-organism that requires complex growth media supplemented with blood or 
serum for its growth in the presence of O2 levels of 2-5% but with an additional need of 5-
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10% CO2, high humidity (96-100%) (microaerophilic environment) and a pH near 7.0 at a 
temperature of 30-37oC. It is equipped against oxidative stress with enzymes such as 
superoxide dismutase, peroxidases and highly active catalase (Kelly et al., 2001). Besides, it 
is urease, catalase and oxidase positive, characteristics which are often explored for 
identification by biochemical testing (Krusters et al., 2006). Urease enzyme appears to be 
vital for the organism’s survival and colonization; its activity is clinically important since it 
forms the basis for several invasive and non invasive tests to diagnose infection (Weeks et 
al., 2000).  
 
2.2 Genes and Genome 
 H. pylori possesses a small, circular, open pan-genome with plasticity zones, a special cluster 
of DNA rearrangements that protects the essential complement of genes by acting as a bed 
for foreign DNA insertion or abrogation (Fischer et al., 2010). The plasticity region encodes 
the type IV secretion system involved in the pathogenesis of this bacterium (Ahmed and 
Sechi, 2005). Israel et al. (2001) discovered that the organism undergoes microevolution and 
give rise to sub-species during prolonged colonization in a single host. Also, genetic 
heterogeneity occurs with strains evolving separately of one another and coupled with the 
fact that the organism is genetically diverse, distinct genotypes have been found to be 
associated with particular geographic regions (Kersulyte et al., 2000).  
 
Accordingly, H. pylori is known as one of the most genetically diverse species due to its high 
mutation rates and frequent recombination events (Fischer et al., 2010). In addition to its 
natural transformation competence, conjugative transfer of genomic islands has to be 
considered as an important source of genetic diversity (Fischer et al., 2010). The diversity 
may facilitate adaptation of the bacterium to its new hosts and to the distinct patterns of the 
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host-mediated immune response as well as persistence for decades despite a changing gastric 
milieu, consequently contributing to the high prevalence of the infection worldwide (Kivi et 
al., 2007).  
 
Furthermore, the genome sequence of two different patients isolates (J99 and 26995) has 
been characterized and compared (Tomb et al., 1997; Alm et al., 1999). The genome of the 
strain 26695 includes 1,587 genes whereas the genome of strain J99 comprises of 1,491 
genes, both with a G + C content of 35- 40%. Notwithstanding, H. pylori genome has an 
approximately 40kb long Cag pathogenicity island which contains over 40 genes, some of 
which codes for the complex type IV secretory system. Also, the genome contains two copies 
of 16S, 23S and 5S rRNA genes which are known as house-keeping genes (Baldwin et al., 
2007).  
 
Several virulent genes have been described in H. pylori such as cytotoxin-associated gene 
(cag A), vacuolating cytotoxin (vacA), the induced by contact with epithelium factor Antigen 
(ice A), the outer membrane protein (oipA) and adhesins (BabA and BabB) (Mansour et al., 
2010; Tanih et al., 2010c; Tanih et al., 2011). In addition, there are other genes that are 
essential to the bacterium for motility and metabolism e.g. flagellin A and urease genes. 
 
Furthermore, the organism has been considered as part of the indigenous biota of human 
stomach, thus identification and characterization of the precise roles of genes and their 
products in its virulence, is extremely important in the prediction of clinical outcomes 
(Proença-Modena et al., 2009).  
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2.3 Pathogenesis and Clinical manifestations 
2.3.1 Pathogenesis 
H. pylori is a well-recognized human pathogen that chronically infects the gastric mucosa of 
up to 50% of the world’s population and has been associated with serious diseases with 
significant morbidity and mortality; however, it represents a serious public health concern 
(Aguilar et al., 2001). A hallmark of H. pylori is its ability to maintain an infection 
throughout the lifetime of an individual however, only 10-15% of those infected actually 
present with symptoms of disease conditions (Frenck and Clemens, 2003).  
 
Acute infection is most commonly asymptomatic and may be associated with epigastric pain, 
abdominal distention or bloating, belching, nausea, flatulence, and halitosis (Meurer and 
Bower, 2002). Prolonged infection and inflammation due to bacterial virulence and host 
genetic factors will lead to gastritis, peptic ulcers (gastric ulcers and duodenal ulcers), gastric 
atrophy and B cell mucosa associated lymphoid tissue lymphoma (Módena et al., 2007). It is 
noteworthy that the clinical manifestations of H. pylori infection are dependent on the 
interplay between pathogen and host, which, in turn, are dependent upon strain-specific 
bacterial factors and/or inflammatory responses governed by host genetic diversity as well as 
environmental factors (Clyne et al., 2007). 
 
a) Virulence determinants of the pathogen 
Virulence determinants encompass all the factors contributing to the evolutionary success of 
the bacterium and the development of the disease in the host (Aguilar et al., 2001). Several 
microbial virulence factors have been identified in H. pylori including cagA and its related 
pathogenicity island (cag PAI), vacA, BabA and BabB. They have been linked to enhance 
pathogenicity of the bacterium. The cag PAI represents a disease-associated locus because it 
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contained approximately 41 putative genes important for increased inflammation and the 
secretion of virulence-related products including IL-8 induction, neutrophil recruitment, 
tyrosine phosphorylation and protein secretion (Peek, 2005). 
 
Some of the genes in cag PAI region encode type IV bacterial secretory apparatus, which can 
translocate CagA protein into the host target cells (Ahmed and Sechi, 2005). Of prime 
importance, cagA encodes the immunoreactive 120-145kDA protein, CagA (Das and Paul, 
2007). The CagA protein has been reported as a marker for more severe disease since it is 
almost always associated with increased inflammation and with strains obtained from patients 
with peptic ulcers and gastric cancer. However, individuals infected with cag A+ strains are 
more likely to develop gastrodudenal ulcers than those infected with cagA- strains (Chan and 
Leung, 2000). 
 
Virtually, all H. pylori strains have vacuolating cytotoxin vacA, which encodes secreted 
bacterial toxin (VacA). VacA induces epithelial cell vacuolization and its expression is 
determined by variations in the signal sequence (s1a, s1b, s1c, s2) and mid-region (m1, m2) 
of the vacA gene (Peek, 2005). Coupled to its well-known vacuolating activity, vacA has 
been reported to induce apoptosis in epithelial cells, affect B lymphocyte antigen 
presentation, inhibit the activation and proliferation of T lymphocytes, and to modulate the T 
cell mediated cytokine response (Ahmed and Sechi, 2005).  
 
The adhesin, BabA is an outer-membrane bound protein encoded by the H. pylori strain-
selective gene babA2, interacting with the blood-group Lewis antigen on gastric epithelial 
cells (Das and Paul, 2007). Strains possessing bab2 are associated with increased risk of 
gastric carcinoma. Another outer membrane protein that might mediate disease is a 
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proinflammatory protein encoded by oipA. The presence of oipA in any strain of this 
bacterium has been linked to more severe inflammation, higher bacterial colonization, 
enhanced mucosal level of IL-8 and duodenal ulceration (Yamaoka et al.,2002). 
 
An independent strain-specific H. pylori locus associated with disease is ice A which exists in 
two allelic forms, iceA1 and iceA2 (Mansour et al., 2010). IceA1 has been suggested to be a 
marker for strains that induce more severe gastric inflammation and injury due to its ability to 
increase tissue damage and disease, its allelic distribution on a minority of clinical strains, its 
linkage disequilibrium with cag A and vacAs1 alleles plus its induction by physiologic events 
that provoke pathologic responses (Peek, 2005). Pathogenic iceA1 strains are significantly 
associated with the presence of peptic ulceration and distal gastric adenocarcinoma (Kidd et 
al., 2001). 
 
b) Host factors 
Host genetic factors might affect H. pylori colonization and development of disease. Genetic 
polymorphism of cytokines and other related legands, receptors and enzymes might influence 
infection (Das and Paul, 2007). Interleukin1β is a pro-inflammatory cytokine endowed with a 
powerful inhibiting activity against gastric acid secretion. Therefore, host genetic factors that 
may affect IL- 1β may determine the quantity of acid secreted which in turn may verify why 
some individuals have gastric cancers or ulcers whilst others do not (Hocker and 
Hohenberger, 2003). 
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2.3.2 Clinical manifestations of H. pylori infections  
After being ingested, H. pylori has to thrive in its ecological niche within the host. The 
gastrointestinal tract (GIT) of humans is a very hostile environment, therefore, in order for 
the bacterium to colonize the gastric mucosa; it must survive the acidic pH of the lumen. H. 
pylori metabolizes urea with its abundant urease enzyme producing ammonia and bicarbonate 
that neutralises the gastric acid (Go, 2002).  
 
Alternatively, VacA permeabilizes the host epithelial cells to urea by functioning as a 
transmembrane pore, thereby allowing the bacterium to manipulate the pH of its environment 
by generating ammonia (Peek, 2005). In addition, several alternative routes for ammonia 
production exist; via enzymatic degradation of diverse amides and amino acids, the bacterium 
expresses two paralogous amidases, AmiE and AmiF, which together with four amino acid 
deaminases probably serve as sources for ammonia in low urea environment. Apparently, 
ammonia is vital to the metabolism and virulence of H. pylori as justified by the numerous 
sources of its supply (Krusters et al., 2006). 
  
The pathogen possesses flagella that allow it to burrow across the viscous gastric mucus to 
reach its niche, close to the stomach’s epithelial cell layer. This motility enables the 
bacterium to resist the muscular contractions (peristalsis) that regularly empty the stomach 
(Ottemann and Lowenthal, 2002). Adhesion of the bacterium to the intestinal epithelium is a 
critical step in enteric colonization. It could use several adherence mechanisms (adhesins) to 
establish contact with the surface of the epithelial cells (Aguilar et al., 2001). Adhesion is 
most likely important for acquisition of nutrients from the host and/or for resistance to 
shedding of the mucus gel layer. 
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Following attachment, the CagA protein is inserted into the host epithelial cell via type IV 
secretion system at the point of contact between H. pylori and the host cell. The translocated 
Cag A protein undergoes tyrosine phosphorylation by Src family kinases and induces 
rearrangements of the host cell cytoskeleton (so called “hummingbird phenotype”). This 
causes disruption of the cytoskeleton, adherence to adjacent cells, intracellular signalling, cell 
polarity   and other cellular activities (Backett and Selbach, 2008). The presence of H. pylori 
in the host triggers a series of inflammatory and immune response in the host (Go, 2002).  
 
The initial migration and activation of inflammatory cells into the gastric mucosa is reliant on 
the production of various proinflammatory cytokines namely IL-8 (Figueirido et al., 
2005).The innate immune system is the first line of defence against invading pathogens. 
CD4+ T-lymphocytes are the major subset lymphocyte involved in immunity against H. 
pylori and are divided into Type 1 T helper (Th1) and Type 2 T helper (Th2) phenotypes. The 
predominance of IL-12 in the human stomach favours the development of a subset of helper 
T cells that tend to produce interferon gamma, which is associated with Th1 cells and 
enhanced cell-mediated immunity (Zevering et al., 1999).  
 
Despite, the vigorous immune responses mounted against H. pylori, the pathogen persists 
within its host by evading immune clearance and subsequently causing disease conditions. It 
could evade immune response via one of the following mechanisms: by siphoning L-arginine 
from a host competitive enzyme, inducible nitric oxide synthetase (iNOS) thereby limiting 
the production of nitric oxide. It also causes an increased level of IL-10, an anti-inflammatory 
peptide that inhibits the secretion of proinflammatory chemokines from macrophages and 
neutrophils (Peek, 2005) added to the fact that it could replicate within epithelial cells and 
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macrophages. Moreover, H. pylori can vary the antigenic repertoire of surface exposed 
proteins (Suerbaum and Michetti, 2002). 
 
Accordingly, the pathogen successfully colonises its host. Combination of H. pylori’s virulent 
attributes, host genetic factors and environmental factors causes a series of changes that 
gradually present with different clinical conditions as shown in Figure 2.1 (Das and Paul, 
2007). However, a typical course of disease begins with chronic superficial gastritis, 
eventually progressing to atrophic gastritis; this appears to be a key event in the cellular 
cascade that results in the development of gastric carcinoma. Other disease conditions in 
which H. pylori has been incriminated include gastroesophageal reflux disease (GERD), non-
ulcer dyspepsia, cardiovascular disease and iron deficiency anaemia (Hardin and Wright, 
2002). 
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Figure 2.1: Proposed interaction between host, environment and H. pylori infection in the 
development of gastric and duodenal ulcers (Das and Paul, 2007). 
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2.4 Diagnosis of H. pylori infections 
Numerous invasive and non-invasive diagnostic tests of different sensitivity and specificity 
have been developed to diagnose H. pylori infections. However, each has its limitation in 
clinical applications (Tiwari et al., 2005). Still, no single test is absolutely reliable to detect 
H. pylori and if feasible, a combination of two tests is recommended (Krogfelt et al., 2005). 
The tests used should depend on clinical circumstances, the likelihood ratio of positive and 
negative tests, cost-effectiveness of the testing strategy and the availability of the tests (Vaira 
et al., 2002; Krogfelt et al., 2005). 
 
2.4.1 Invasive tests 
These tests detect the micro-organism in a biopsy sample of the upper gastric mucosa 
obtained at upper gastro-intestinal endoscopy (Lin et al., 2004). These biopsy-based tests 
which require an endoscopic procedure are uncomfortable to the patients. Also, there is the 
possibility of false negative results due to sampling error because H. pylori infection in the 
stomach maybe patchy. This could be as a result of intestinal metaplasia or re-growth after 
failed eradication (Kato et al., 2001).  
 
Furthermore, long acid suppressive treatment may decrease the number of H. pylori 
colonizing the gastric antrum, with an increase in the numbers colonizing the fundus (Logan 
and Walker, 2002). To salvage this situation, multiple biopsies have to be taken both from 
gastric antrum and corpus in order not to miss the bacterium. On the other hand, these tests 
are able to detect active infections while being highly specific with a very high predictive 
value.     
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a) Rapid Urease Test 
This is a simple, inexpensive, fast and widely available test whose principle rests on the 
powerful urease activity of H. pylori and its exclusive ecological niche in the gastric mucosa 
protected from competition with other bacteria (Mödena et al., 2007). Urease activity in the 
biopsy sample is detected by the rise in pH (seen as colour change) which follows ammonium 
ion production from urea (Dönmez-Altuntas and Güven, 2002).  
 
It is limited, however, by false negative results due to decreased urease activity, caused either 
by recent ingestion of antibiotics, bismuth compounds and proton pump inhibitors, gastric 
atrophy and contamination with the bile (Meurer and Bower, 2002). Commercially available 
test kits include CLO test (Campylobacter-like organism test) that has been proven to be of 
high sensitivity and specificity after an hour (Krogfelt et al., 2005). 
 
b) Histology 
Histological evaluation has traditionally been the “gold standard” method for diagnosing             
H. pylori infection (Orhan et al., 2008). It allows for the definitive diagnosis of infection, as 
well as the degree of inflammation or metaplasia and the presence/absence of MALT 
lymphoma or other gastric cancers in high risk patients (Tanih et al., 2008). In clinical 
practice, knowledge of the microscopic appearance of the gastric mucosa aids in therapeutic 
decision making and in the planning of follow-up arrangements (Sipponen et al., 1997). H. 
pylori colonized with high density can be observed in routine Hematoxylin-eosin (HE)-
stained section (Orhan et al., 2008).  
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However, to show the characteristic morphology and to detect lower density of the organism, 
special stains are to be employed such as Gram, Giemsa, Genta or Warthin-starry stains 
(Ndip et al., 2003). The speed and simplicity of the modified Giemsa stain technique makes it 
the method of choice in routine clinical practice (Gatta et al., 2003). However, none of these 
stains are specific for H. pylori, and the Helicobacter-like organisms may cause false positive 
results with these stains (Orhan et al., 2008). Its accuracy depends on the stain selected and to 
a great extent on the experience of the observer (Tiwari et al., 2005). 
 
i) Immunohistochemical staining 
Immunohistochemical staining with specific polyclonal antibodies to visualize H. pylori in 
gastric biopsies has also been available since 1988. Contrary to histology, this method helps 
to identify the organism at low magnification, even in small numbers (Gental et al., 1994) 
and also visualizes its coccoid forms. It could be better than Urea Breath test (UBT) since 
coccoid forms of H. pylori cannot produce urease, its activity on which UBT is based (Orhan 
et al., 2008). It is simple, sensitive, specific, reproducible and easy to perform. 
 
ii) Fluorescent in situ hybridization (FISH) 
FISH is a genotype-based technique that can detect H. pylori and its macrolide-resistant strain 
in formalin-fixed, paraffin-embedded specimens (Jüttner et al., 2004) and also in 
deparaffinized gastric biopsies (Yilmaz et al., 2007). It involves rRNA-targetted 
fluorescence-labeled oligonucleotide probes binding to either 16S rRNA (Can et al., 2005) or 
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23 rRNA sequences (Caristo et al., 2008). This technique is very valuable in situations in 
which results from conventional culturing and antibiotic susceptibility testing are not 
available for clinical decision making (Rüssman et al., 2003). Of major advantage is the fact 
that, it can be used for accurate determination of macrolide susceptibility, thus providing the 
clinician with important information with which to make a proper treatment recommendation. 
It is promising because it provides rapid, easy-to-implement, reliable, cost-effective and 
culture-independent method for routine diagnosis (Can et al., 2005). 
 
c) Culture 
Microbiogical isolation of the organism is the theoretical “gold standard” for the detection of 
H.pylori infections. Cultures could be recovered from gastric biopsies, brushings, aspirate, 
feces, vomitus, dental plaque and saliva, which have been used as potential specimen sources 
(Ndip et al., 2003). Gastric mucosal biopsy materials are currently considered the easiest and 
best source to culture the organism. They can be collected and transported in 0.9% 
physiological saline, commercially available Portagerm pylori (Biomerieux), Stuart’s 
transport medium (Ndip et al., 2003) and Brain Heart Infusion broth+20% glycerol+ cysteine 
(Tanih et al., 2010). 
 
Culture can be performed on both solid and liquid media, e.g. Columbia blood agar medium 
supplemented with Skirrow’s antibiotics (10mg vancomycin, 2.500 units polymyxin B, 5mg 
trimethoprim) and 7% defibrinated horse blood  to select specifically for H. pylori (Megraud 
and Lehours, 2007). Since it contains blood, the medium must be used within two weeks, if 
optimum culture conditions are to be maintained (Ndip et al., 2003). Other media that could 
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also be used include; Chocolate Agar, Marshall Brain Heart Infusion medium (BHI) and 
Wilkins-Chalgren Agar with horse blood. Incubation of inoculated plates is done under 
microaerophilic conditions (5%O2, 10%CO2, and 85% N2) which could be produced by 
Campy Pak (Oxoid Ltd, UK) at 37oC for 4-7days (Velapatino et al., 2006). 
 
The bacterium is identified based on colony morphology, gram staining, and positive reaction 
to oxidase, catalase, and urease assays (Nguyen et al., 2009). Various conditions can affect 
the survival rate of H.pylori e.g. the time lapse between sampling and culture, transport 
temperature, transport media and duration of exposure to air (Yuen et al., 2005). The success 
rate of isolation also depends on the clinical expertise of the microbiology laboratory ranging 
from 30% to 73% (Destura et al., 2004). Although bacteriological culture procedure is costly, 
time consuming and labour intensive, it gives insight into the antibiotic susceptibility of 
strains, a factor important to the clinician for the effective management of H. pylori 
infections. It also provides information regarding the virulence factors of the organism 
especially cag A and vac A alleles (Módena et al., 2007). 
 
d) Polymerase Chain Reaction (PCR) 
PCR is an extremely sensitive and specific method of detecting H.pylori in gastric biopsy, 
saliva, feces and gastric juice samples (Dönmez-Altuntas and Güven, 2002). Minute 
quantities of target DNA are amplified with the PCR technique thus maximizing the 
sensitivity of detection. The 16SrRNA gene of H.pylori is a highly specific target for 
amplification and has been previously used to help reclassify the organism (Tiwari et al., 
2005).  
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This molecular technique is advantageous in identifying virulence genes of the infecting 
strain (cagA being the main determinant), which might have implications for the 
development of severe disease or efficacy of eradication (Tanih et al., 2008). Among the 
draw backs are i) the possible existence of Taq polymerase inhibitors which can decrease the 
sensitivity of the reaction ii) the possible contamination of the specimen by exogenous H. 
pylori DNA which alters specificity. Notwithstanding, several methods have been proposed 
to increase the sensitivity of PCR (Mégraud and Lehhours, 2007). A positive result detected 
by any of the molecular techniques does not indicate current infection as it can also detect the 
DNA of dead organisms (Ricci et al., 2007). 
 
2.4.2 Non-invasive tests 
The non-invasive tests are more convenient and equally accurate in diagnosing H.pylori 
infections. They obviate the need for endoscopy which is invasive and discomforting in 
nature (Kato et al., 2001), and thus are appropriate for large scale community based studies or 
routine screening of children, the group in which most infections start (Mackay et al., 2003). 
These tests are relatively inexpensive and rapid, all are proxy measurements of infections; 
thus validation typically using histology or culture as the gold standard must be performed 
initially (Frenck et al., 2006). These tests can either be active or passive (Oderda et al., 2001). 
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a) 13C-Urea Breath test (UBT) 
13C- UBT is the gold standard in non-invasive diagnostic testing for H.pylori infection 
(Zambon et al., 2004). It is based on the principle that, a solution of urea labeled with 
13Carbon or 14 Carbon is rapidly hydrolyzed by the urease enzyme of H. pylori. 13C- labeled 
urea has the advantage of being non radioactive and thus safer for children and women of 
child bearing age. The resulting CO2 is absorbed across the gastric mucosa and hence via the 
systemic circulation, excreted as 13CO2 in the expired breath (Logan and Walker, 2002). 
 
Differences in 13CO2 expired may reflect the extent of the infection. This may also be 
affected by the strain-dependent urease activity, duration of contact between 13C-labelled urea 
and the infected gastric mucosa that may vary because of individual differences in gastric 
acid secretion and motility (Nigel Bird, www.packardinstrument.com). UBT is theoretically 
subjected to false positives from urease positive bacteria present in the oral cavity. It is a 
relatively inexpensive, reliable and valuable test for establishing absence of infection after 
treatment (Krogfelt et al., 2005).   
 
b) Serology 
H. pylori infection induces an immune response through the production of immunoglobulins 
to organism-specific antigens. These antibodies can be detected in serum or whole blood 
samples. Circulating IgG antibodies can be detected by Enzyme Linked Immunosorbent 
Assay (ELISA) or latex agglutination (Logan and Walker, 2002). ELISA relies on the 
hydrogen bond formed between the antibodies (abs) and antigen (ags) which is monitored by 
a colour change when there is a reaction of ag-ab (Oderda et al., 2001). Individuals vary 
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considerably in their antibody response to this organism and no single antigen is recognized 
by sera from all subjects.  
 
The accuracy of serological tests therefore depends on the antigens used in the test, making it 
essential that H. pylori ELISA is locally validated (Logan and Walker, 2002). These tests are 
generally simple, reproducible, and inexpensive and can be done on stored samples. 
Furthermore, they are useful in identifying certain strains of more virulent H.pylori by 
detecting antibodies to virulent factors associated with more severe disease and complicated 
ulcers, gastric cancer and lymphoma (Hardin and Wright, 2002). Since antibody titres fall 
only slowly after successful eradication, serology cannot therefore be used to determine 
H.pylori eradication (Lin et al., 2004).  
 
c)  Stool Antigen test 
The stool antigen test (Premier Platinum Hp SA Meridian Diagnostics, Inc., Cincinnati, Ohio) 
has been successfully used to detect the presence of H.pylori in stool samples (Lin et al., 
2004). It is well standardized, easy to perform, less expensive and relies on the detection of 
H.pylori antigens in feces by enzyme immunoassay (Ndip et al., 2004).  It utilizes an 
immunoaffinity purified polyclonal anti-H. pylori rabbit antibody absorbed to micro wells. 
The fecal samples can be stored at -70oC until the test is performed.  
 
Results of the test are assigned to positive, negative or equivocal value on the basis of the 
manufacturer’s recommended cut off values (Shepherd et al., 2000). Highly sensitive and 
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specific, the stool antigen test reverts to negative from 5 days to a few months after 
eradication of the organism. Hence, it is useful in confirming eradication (Meurer and Bower, 
2002). 
 
2.5 Epidemiology of H. pylori infections 
H. pylori infections in humans have a worldwide distribution. Investigation of the incidence 
of the organism has been scarce because acute infection does not present with diagnostic 
symptoms, hence it is impossible to pinpoint the time a person acquires the infection (Logan 
and Walker, 2001). Notwithstanding, incidence of the infection can be determined by 
extrapolation from the prevalence data. 
 
 
 2.5.1 Prevalence and geographical distribution. 
The prevalence of infection seems mostly to depend on the rate of acquisition but also on rate 
of loss of infection and the length of the persistence period between acquisition and loss 
(Malaty et al., 1999). Based on these factors, prevalence of infection varies, both among 
countries and between different racial groups’ resident within the same country (Segal et al., 
2001; Krusters et al., 2006). The highest rates of H. pylori prevalence are in Eastern Europe, 
Asia, and many developing countries and developing populations in developed countries (e.g. 
Native Americans) (Tkachenko et al., 2007). 
 
In industrialized countries, 40-50% of the population is infected and infection is low early in 
childhood and slowly rises with increasing age; the higher prevalence of infection among the 
elderly thus reflects a birth cohort effect with higher infection rates in the past (Gold, 2001). 
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On the other hand, the prevalence of infection in developing countries is higher about 90%, 
acquired early in childhood and infection rates rise rapidly in the first 5 years of life and 
remain constantly high thereafter. Although, high prevalence rates have been reported in 
developing countries, these rates are lower in some developing countries with better 
industrialization, public health and living conditions; however, the rate is still several times 
much higher than that reported in developed countries (Aguilar et al., 2001).  
 
2.5.2 Factors correlated with prevalence 
Ethnicity, genetic predisposition, age, sanitation, educational level, socio-economic status, 
and living conditions are important determinants of H. pylori prevalence (Mittal and Mathew, 
2003; Khalifa et al., 2010; Tanih et al., 2010a). 
 
a) Age 
Acquisition of H. pylori infection appears on the basis of age-specific prevalence to be 
relatively constant over time in some population. Age is positively correlated with H. pylori 
prevalence and has been demonstrated both in developed and developing countries (Huang et 
al., 2004; Rodrigues et al., 2004). Consistently, the prevalence of infection has been found to 
be higher in adults than in children, and this may be attributable either to new acquisition of 
infection among the population or the effect of birth cohorts, each with a different rate of 
acquisition in childhood (Malaty, 2007).  
 
However, there is little age-related increase in prevalence in developing countries given that 
the transmission of infection already occurs at a high rate in children. This is due to the fact 
that children are more susceptible to infection because of their lack of knowledge with 
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reference to hygiene and their increased susceptibility during episodes of achlorhydria 
induced by gastroenteritis (Luman, 2002). 
 
b) Ethnic and Genetic predisposition 
The prevalence of H. pylori infection varies between geographical locations i.e. between 
developed and developing countries. Although, the organism is acquired at childhood in both 
countries, black children have been found to have a higher rate of initial acquisition, a lower 
rate of loss of infection and a higher rate of reinfection than the white children (Malaty et al., 
2002).Marked differences in seroprevalence of H. pylori have been observed between various 
ethnic and racial groups living in the same region (Bardhan, 1997). For example, in USA the 
overall prevalence of H. pylori infection is estimated at 30-40%, but it remains much higher 
in certain ethnic groups such as the African-American and Hispanics (Go, 2002). 
 
In South Africa, increase in H. pylori prevalence with age as well as among coloreds (68.4%) 
than in whites (59.5%) has been noted in the Eastern Cape Province (Tanih et al., 2010a). 
Notwithstanding, variation in acquisition of infection among ethnic and racial groups appears 
to be primarily related to differential exposure (e.g. cultural background, social, dietary and 
environmental factors) and not to differences in genetic predisposition although, genetic 
predisposition to infection is also feasible (Aguilar et al., 2001). 
 
c) Socioeconomic factors 
Apparently, the variation in prevalence rates between developed and developing countries 
have purportedly been associated with the socioeconomic status. A lower socioeconomic 
status has been indicated as a cause for the higher age-specific H. pylori prevalence in 
developing countries. Socioeconomic status has been reported to be positively correlated with 
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H. pylori prevalence and could be described in terms of occupation, income level, social 
class, living standards, sanitation, urbanization and educational level (Lehours and Yilmaz, 
2007; Dube et al., 2009b).  
 
In addition, Goldman et al. (2006) in their study indicated that H. pylori prevalence was 
positively associated with number of siblings, presence of pet cats and birds in the household 
and antecedents of gastritis among family members, in symptomatic children population in 
Buenos Aires, Argentina. Other poverty-related factors such as overcrowding, bed sharing, 
large sibling size, lack of domestic hot water have been reported to influence the prevalence 
rate (Mitipat et al., 2005). Combined, these factors are likely to increase the risk of infectious 
diseases in general. 
 
2.5.3 Transmission of H. pylori infections 
 2.5.3.1 Reservoirs  
The human gastric mucosa appears to be the most suitable environment for the survival of 
this organism (Van Duynhoven and de Jonge, 2001) thus it is the major reservoir.  Other 
environmental or animal reservoirs have been suggested which could be involved in indirect 
transmission, such as food, animals (pigs, sheep, cats), water sources and the midgut of 
housefly (Khalifa et al., 2010).  
 
2.5.3.2 Possible routes of transmission 
H. pylori is one of the human pathogens with the highest prevalence around the world; yet its 
exact modes of transmission are still uncertain. Despite the poor knowledge on how the 
bacterium is being transmitted, the extensive prevalence, the clustering of cases in the 
families, the higher prevalence of H. pylori seropositivity rates among persons living in 
 40 
 
institutions or other crowded conditions and the lack of a plausible environmental reservoirs 
strongly suggest that direct transmission by person-to-person contact is the primary mode of 
transmission (Khalifa et al., 2010). 
 
Transmission via person-to-person contact is dependent on the degree of contact between 
susceptible and infected individuals, in tandem with the degree of crowding and age-
distribution among those susceptible to infection and those that are infected (Das and Paul, 
2007). It may occur by one or combination of three means; oral-oral, gastro-oral or fecal-oral 
routes but determining a dominant route is not an easy task. These different routes of 
transmission may be predominant in different geographical settings (Engstrand, 2001).  
 
More elaborately, the oral-oral transmission pathway has been suggested as the prevailing 
route in developed countries characterized with improved sanitation, and proper water 
treatment (Brenner et al., 1999). Saliva from the oral cavity could also act as a vehicle of 
transmission since H. pylori can be isolated from saliva and dental plaques (Chitsazi et al., 
2006).On the other hand, studies from developing countries with low socio-economic status 
and poor management of drinking water such as the rural areas, advocate that environmental 
factors are essential (Dube et al., 2009a). 
 
 Feces-contaminated water may be a source of infection. Successful identification of the 
pathogen from the feces of Cameroonian and Iranian children though by different diagnostic 
methods proved that H. pylori can survive in the intestinal tract and be shed into the 
environment along with feces (Ndip et al., 2004; Falsafi et al., 2009). Diarrhoea is a common 
childhood ailment and, coupled with reduced awareness of hygiene in children and the liking 
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for putting objects into their mouths, the faecal-oral route of transmission can take place 
through sharing of food or toys touched by contaminated fingers (Luman, 2002).  
 
However, transmission by oral-oral route is also feasible as it can be potentiated by specific 
eating habits for instance, the premastication of food by mothers before feeding their children 
in some African countries and the use of a common spoon by the mother and child (Luman, 
2002). This is because transient colonization in the mouth could occur in mothers with free 
reflux (Luman, 2002). It is therefore reasonable to suggest a direct gastro-oral route of 
transmission mediated by refluxed gastric juice (Luzza et al., 2000). This mode of 
transmission has been postulated in young children among whom vomiting and gastro-
esophageal reflux is common. Vomitus could act as a vehicle of transmission and infection 
could occur through ingestion of food or exposure to objects contaminated with vomitus 
colonized by H. pylori (Luman, 2002).  
 
2.6 Treatment of H. pylori infections: Mitigating factors and prospective natural 
remedies 
H. pylori infection is a serious, chronic, progressive and transmissible infection associated 
with significant morbidity and mortality, which alone emphasizes the priority of developing 
adequate prophylactic or therapeutic measures (Scarpignato, 2004). Development of a 
successful treatment for H. pylori infection has been fraught with difficulty. Its location 
within the  stomach (that is, the mucus lining the surface epithelium, deep within the mucus-
secreting glands of the antrum, attached to cells and even within the cells) provides a 
challenge for antimicrobial therapy (Romano and Cuomo, 2004).  
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In addition, the gastric mucosa is a hostile environment for antimicrobial therapy because 
drugs must penetrate thick mucus and may need to be active at pH values below neutral 
(Malekzadeh et al., 2004; Manyi-Loh et al., 2010a). Moreover, emerging bacterial resistance 
presents an added challenge (Hardin and Wright, 2002). 
 
The purpose of treatment of H. pylori infection in any clinical situation is eradication of the 
bacterium from the fore gut or stomach. Eradication is defined as a negative test for the 
bacterium four weeks or longer after treatment (Harris and Misiewicz, 2002). For successful 
eradication of the bacterium, it is imperative that the clinician be aware of the current 
antimicrobial susceptibility profiles of the isolates within the region (Sherif et al., 2004). 
Consequently, antibiotic recommended for patients may soon differ across regions of the 
world because different areas have begun to show resistance to particular antibiotics. Such 
regional variation in resistance patterns probably reflects geographical variation in local 
antibiotic-prescription practices, and antibiotic use and abuse, as drug control is much tighter 
in some areas than others (Ndip et al., 2008). 
 
2.6.1 Drugs used for treatment 
H. pylori infections are treated with drugs that kill the bacteria (antibiotics), reduce stomach 
acid [H2 blockers and proton pump inhibitor (PPI)] and protect the stomach lining (bismuth 
compounds). 
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a) Bismuth compounds 
The discovery of H. pylori in 1983 led to renewed interest in bismuth compounds, because 
these were found to successfully treat the infection in combination with antibiotics (Ford et 
al., 2008). Bismuth compounds (colloidal bismuth sub citrate and bismuth subsalicylate) may 
reduce the development of resistance to co-administered antibiotics and are also effective at 
treating H. pylori strains with established resistance to other antibiotics (Andersen et al., 
2000). These compounds act by reducing intracellular ATP levels and interfere with the 
activity of urease enzyme, a key enzyme of H. pylori (Romano and Cuomo, 2004). Also, they 
induce the formation of an ulcer-specific coagulum, preventing acid back diffusion (Meurer 
and Bower, 2002) and inhibit protein and cell wall synthesis as well as membrane function 
(Bland et al., 2004).  
 
Furthermore, they cause an increase in the synthesis of prostaglandin E2 (Sandha et al., 1998), 
detachment of H. pylori from the gastric epithelium and a reduction in capsular 
polysaccharide production (Romano and Cuomo, 2004). Therefore, the properties of bismuth 
compounds are bactericidal for H. pylori (Larsen et al., 2003).  
 
The bismuth compounds are extremely potent cytotoxic agents when attached to a 
monoclonal antibody as these can target leukemia, lymphoma and other tumors. Interestingly, 
H. pylori is incriminated in mucosa associated lymphoid tissue lymphoma, thus there is a 
clear connection between anti-tumor activity and bismuth compounds (Wotherspoon, 1998). 
Side effects encountered with this drug include darkening of oral cavity and stool, nausea and 
gastrointestinal upset (Stenstrôm et al., 2008).  Recently, bismuth containing regimen has 
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been recommended as a potential first line therapy, because there have been concerns 
expressed that PPI-based triple therapies for H.pylori do not lead to a satisfactory eradication 
rate (Ford et al., 2008). 
 
b) Acid Reducers 
Two types of acid-suppressing drugs might be used: H2 blockers and PPI. H2 blockers work 
by blocking histamine, which stimulates acid secretion. They include; cimetidine, ranitidine, 
famotidine and nizatidine. On the other hand, PPI suppress acid production by halting the 
mechanism that pumps the acid into the stomach. They also include; omeprazole, 
lansoprazole, rabeprazole, pantoprazole and esomeprazole (Gendull et al., 2003). 
 
H. pylori  has evolved multi-faceted acid-adaptive mechanisms (Wen et al., 2003). Increasing 
the gastric pH with the use of histamine H2 receptor antagonist (H2RA) or PPI has been 
shown to improve the effectiveness of antibiotic therapy. In the presence of ulcer disease, PPI 
have largely replaced H2RA because of their ability to provide more rapid pain relief and 
better control of pH (Meurer and Bower, 2002). PPI’s also display several pharmacological 
actions that promote eradication. These include: 
i) An antibacterial action against H. pylori (Nakao and Malfertheiner, 1998). 
ii) By increasing intra gastric pH, they allow the microorganisms to reach the growth phase 
and become more sensitive to antibiotics such as amoxicillin and clarithromycin (Farthing et 
al., 1998; Scott et al., 1998). 
ii) They increase antibiotic stability and efficacy (Erah et al., 1997).  
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iv) By reducing gastric emptying and mucus viscosity, they increase the gastric residence 
time and mucus penetration of antimicrobials (Pedrazzoli et al., 2001). 
 
 In addition, some of these anti–ulcer drugs show in vitro synergy when tested with some 
antibiotics. Seemingly, the increased absorption and tissue penetration of antimicrobial agents 
that occur with elevated gastric mucosal levels caused by omeprazole may contribute to the 
observed synergy (Calafatti et al., 2000). 
 
c)  Antibiotics 
H. pylori is susceptible in vitro to commonly used antibiotics such as; amoxicillin (AMOX), 
tetracycline (TET), metronidazole (MET) and clarithromycin (CLR) (Alarcón et al., 1999). 
Of the H. pylori isolates collected in Cameroon, Ndip et al. (2008) found 56.1% to be 
susceptible to TET, 55.3% to CLR, 14.4% to AMOX and only 6.8% to MET. Currently, these 
antibiotics are administered in combination, with no single agent ever used as monotherapy 
because of lack of efficacy and the potential development of resistance (Hardin and Wright, 
2002). 
 
Metronidazole (prodrug) is highly active against H. pylori, and requires activation by 
bacterial nitroreductases (Meurer and Bower, 2002). The bacterium possesses a number of 
enzymes with the potential to reduce MET. The reduced nitroimidazole cause loss of the 
helical structure of bacterial DNA, break strands and thus, impair bacterial infection (Romano 
and Cuomo, 2004). However, other studies have reported high rates of resistance to this drug 
(Ndip et al., 2008; Tanih et al., 2010b). MET can have unpleasant adverse effects (e.g. 
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nausea, a metallic taste, dyspepsia) and a disulfiram-like reaction with alcohol consumption 
(Stenström et al., 2008). 
 
Clarithromycin is recognized as the key antibiotic for H. pylori treatment because of its 
powerful bactericidal effect in vitro compared with the other available molecules (De 
Francisco et al., 2007). Co-administration with PPI significantly increases the concentration 
of CLR in the antral mucosa and the mucus layer (Meurer and Bower, 2002; Njume et al., 
2009). Results of studies showing approximately 90% H. pylori eradication with triple 
therapy regimens using CLR have led to the widespread use of this antibiotics (Romano and 
Cuomo, 2004), though it is more expensive than other antibiotic agents. Adverse effects with 
CLR include a bitter metallic taste, gastrointestinal upset and diarrhea (Ables et al., 2007; 
Stenström et al., 2008). 
 
Amoxicillin, semi synthetic penicillin is an effective antibiotic for H. pylori infection. Its 
action against H. pylori is pH dependent and therefore requires co-administration with a PPI 
(Meurer and Bower, 2002). It inhibits the synthesis of bacterial cell wall after absorption into 
the bloodstream and subsequent delivery into the gastric lumen (Romano and Cuomo, 2004). 
Side effects include gastrointestinal upset, diarrhea and headache (Stenström et al., 2008). 
 
Tetracycline has demonstrated in vitro efficacy against H. pylori and is active at low pH 
(Romano and Cuomo, 2004). It is inexpensive and is a close derivative of the polycyclic 
naphthacene carboxamides.Therefore; it inhibits protein synthesis and bind specifically to the 
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30S ribosomal subunit. Tetracycline can cause discoloration of teeth in children, 
photosensitivity reaction and gastrointestinal upset (Hardin and Wright, 2002). 
 
Furazolidone, a synthetic nitro furan appears to be effective for many H. pylori strains which 
are resistant to MET (Meurer and Bower, 2002). However, it is described as an alternative to 
MET; patients should be warned against using alcohol or monoamine oxidase inhibitors 
(Gendull et al., 2003). 
 
2.6.2 Treatment Strategy 
The treatment of H. pylori infection can be likened to the treatment of tuberculosis because it 
is a multidrug regimen and an adequate length of time is needed to eradicate the organism 
(Meurer and Bower, 2002). Combination drug regimens are essential to minimize the risk of 
promoting antimicrobial (namely to MET and or CLR) resistance (De Boer and Tytgat, 
2000). The only conditions, for which such treatment is strongly recommended on the basis 
of unequivocal evidence, are peptic ulcer disease and low grade gastric MALT lymphoma 
(Tanih et al., 2009). Monotherapy in which antibiotic agents alone were used in the 
eradication of the bacterium was inefficient, making it imperative to use dual, triple or even 
quadruple therapy (Alarcón et al., 1999). 
 
Dual therapy regimen refers to the combination of PPI’s or Ranitidine bismuth citrate (RBC) 
and one antibiotic usually AMOX or CLR (Wu and Sung, 1999). The first dual therapy 
combining omeprazole with AMOX had unpredictable efficacy ranging from 20% to 90% 
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(Laine et al., 1997). The dual therapy is, however, more reproducible when AMOX is 
replaced with CLR (Wu and Sung, 1999).  
 
Triple therapy regimen is the most popular and standard treatment regimen for the cure of H. 
pylori infection (De Boer and Tytgat, 2000). It consists of an acid-suppressant (PPI or RBC) 
and two antimicrobials (Wu and Sung, 1999). The first PPI- based triple therapy was 
described by Bazzoli et al. (1993) and its good efficacy (eradication rate of more than 80%) 
has been supported in several studies in Europe (Malfertheiner et al., 1999) and Canada 
(Zanten et al., 1999). The choice of antibiotics determines the efficacy of the PPI-based triple 
therapy, thus CLR being included in the therapy ensures high efficacy and reproducible 
results (Wu and Sung, 1999). 
 
Because bacterial resistance to MET or CLR results primarily from previous treatment 
failure, first choice treatment should never combine CLR and MET in the same regimen 
(Romano and Cuomo, 2004). In fact, even though this combination is highly effective, 
patients who are not cured will have at least single, and usually double, resistance (Peitz et 
al., 2002) and no viable empirical treatment remains afterwards. RBC-triple therapy has 
proven to be effective in eradicating H. pylori with cure rates ranging from 80% to 96% 
(Laine et al., 1997). One week RBC based triple therapy is now increasingly considered as an 
effective regimen for H.pylori eradication (Savarino et al., 1997). 
 
Quadruple therapy regimen consists of bismuth, a PPI and two antibiotics (Malekzadeh et al., 
2004). Currently, quadruple therapy is mainly reserved as a second line regimen in cases of 
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treatment failure and even as an alternative first-line treatment for eradicating H. pylori 
infection, especially in areas of high prevalence of antibiotic resistance (Mirsattari et al., 
2010). Most common putative quadruple therapies currently in use include bismuth-based 
and levofloxacin-based therapies (Gisbert and Javares, 2002).  
 
In addition to H. pylori eradication therapy, patient’s education about the need for effective 
eradication therapy and the necessity of completing the initial drug regimen is critical. 
Confirmation of the eradication of the bacterium from the fore gut is necessary after 
treatment. 
 
2.6.3 Factors affecting the effectiveness of treatment regimens 
Factors implicated in treatment failure include drug costs and availability, number of H. 
pylori cells in the gastric mucosa, treatment side effects, lack of penetration of antibiotics into 
the depth of gastric mucosa (Wong et al., 2002), antibiotic inactivation by pH, lack of 
compliance by patients, lack of correlation between in vitro susceptibility test and in vivo 
efficacy and the presence of H. pylori strains with primary or secondary resistance to the 
antimicrobial agents used (Bytzer and  O’Morain, 2005), duration of treatment and antibiotics 
dosage (Gendull et al., 2003).  
 
Antimicrobial resistance is increasing and regional variations in susceptibility and resistance 
patterns maybe ascribed to differences in local antibiotic prescription practices, antibiotic 
usage in the community and mass eradication programmes for H. pylori (Destura et al., 
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2004). Until recently, the recommended duration of therapy for H. pylori eradication was 10 
to 14 days (Ables et al., 2007). Potential benefits for shorter regimens include better 
compliance, fewer adverse drug effects, and reduced cost to the patient (Meurer and Bower, 
2002). Low gastric pH seems to affect the activity of antibiotics since most are active at 
neutral pH.  
 
The minimal bactericidal concentrations (MBC) and minimal inhibitory concentrations 
(MIC) of most antibiotics against H. pylori (except MET and TET), are dependent on the pH 
of the environment (Mégraud and Lamouiatte, 2003; Njume et al., 2009). At pH values lower 
than 7 or 7.4, the MIC increases. This is why PPI’s are used in therapy so as to increase the 
pH of the stomach, to allow better antimicrobial activity (Farthing et al., 1998). In patients 
who are acid hyper secretors, the pH remains low. Consequently, antimicrobial activity may 
be insufficient to eradicate the bacteria. As a result, increasing the dosage of PPI in the 
treatment regimen may have beneficial effects (Malekzadeh et al., 2004). 
 
The most important causes of treatment failure are poor compliance on the part of the patients 
and the development of bacterial resistance to antimicrobial agents (Huynh et al., 2004). 
Patient compliance can only be improved by choosing a simple and well tolerated treatment 
regimen. Also, patients should be educated on the significance of eradication therapy 
(Stenström et al., 2008). 
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2.6.4 Antimicrobial resistance  
Resistance of H. pylori to the limited range of antibiotics that have efficacy in its treatment 
can severely affect attempts to eradicate the bacteria. The prevalence of bacterial resistance in 
certain geographical areas can influence the selection of first line eradication regimen in 
those regions (Malekzadeh et al., 2004). Bacterial resistance to antimicrobials, however, 
could be either primary (that is, present before therapy) or secondary (that is, develop as the 
result of failed therapy (Romano and Cuomo, 2004).  
 
Primary resistance in H. pylori has been reported in MET (6-95%), CLR (0-17%), and TET 
(0-6%) in different countries (Boyanova et al., 2000; Huynh et al., 2004). The issue of 
resistance primarily concerns MET and CLR, however, acquired resistances to AMOX and 
TET have also been reported, although they are extremely rare (Kwon et al., 2000; Kim et 
al., 2003). Recently, an alarming rise in resistance of H. pylori to AMOX has been reported, 
especially in African countries namely, Cameroon, Nigeria and South Africa where stringent 
control of drugs is lacking (Ndip et al., 2008).  
 
Metronidazole-containing regimens have recently been shown to have limited effectiveness 
because of the increasing prevalence of resistance to this drug. Its prevalence varies from 
10% to 90% in different countries (Wu and Sung, 1999). For example, a resistance rate of 
28.6% for MET was reported by Boyanova et al. (2000) in their attempt to assess the primary 
resistance of four antimicrobials against clinical isolates of H.pylori circulating in Sofia, 
Bulgaria. 
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Furthermore in Cameroon, Ndip et al. (2008) documented a very high resistance to MET 
while Tanih et al. (2010b) reported a rate of 95.5% in South Africa. Seemingly, Mollison et 
al. (2000) in their study conducted in Australia registered a resistance of 36% of H. pylori 
isolates against MET. Increasing the dosage of MET administered generally improves the 
result of the therapy when treating MET-resistant H. pylori strains (Stenström et al., 2008). 
The generally high prevalence of metronidazole resistance, for example, is probably as the 
result of the frequent, uncontrolled use of nitroimidazole derivatives for the treatment of 
protozoan infections and gynecological problems (Ndip et al., 2008). 
 
Primary clarithromycin resistance is increasing worldwide and it has been regarded as the 
main factor reducing the efficacy of eradication therapy (De Francisco et al., 2007). 
However, the prevalence rate of CLR resistance is 12.9% in the U.S and it is as high as 24% 
in some European countries (Huynh et al., 2004). Acquired resistance to CLR frequently 
develops in individuals after initial treatment failure (Wu and Sung, 1999). These CLR-
resistant strains of H. pylori can be treated using a regimen containing levofloxacin (Hsu et 
al., 2008). Nevertheless, there is a trend of rising resistance due to widespread use of CLR in 
the treatment of upper respiratory tract infections. 
 
The increasing prevalence of antimicrobial resistance jeopardizes the success of therapeutic 
regimens aimed at the eradication of infection (Deltenre, 1997). Therefore, clinicians should 
choose the appropriate combination of drugs based on sensitivity patterns provided by a local 
reference centre (Meurer and Bower, 2002). Ideally, in cases of treatment failure, the 
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antibiotic sensitivity pattern of the organism should be established before the second line 
therapy is chosen (Destura et al., 2004). 
 
2.6.5 Prospective natural remedies 
The current increasing prevalence of antimicrobial resistance and its negative impact on the 
eradication treatment regimens has brought forth the quest for novel therapeutic approaches. 
A non-antibiotic agent, which is readily available, inexpensive, and effective and free from 
side effects, might be of utmost importance for the eradication of H. pylori (Ndip et al., 
2007). Natural foods can be attractive as an alternative treatment for H. pylori.  
 
Dietary approaches that would keep H. pylori density and infection-mediated inflammation 
on a low level could be of considerable interest in developing low-cost, large-scale alternative 
solutions to prevent or decrease H. pylori colonization (Calvet et al., 2000). In this respect; 
probiotics may close the therapeutic gap. A probiotic is defined as a living microbial species 
that, on administration, may have a positive effect on bowel micro-ecology and improve 
health conditions (Fuller, 1991). Probiotics have been proven to be useful in the treatment of 
several gastrointestinal diseases and can be beneficial in H. pylori-infected subjects for 
several reasons.  
 
At present, the most studied probiotics are lactic acid-producing bacteria, particularly 
Lactobacillus and Bifidobacterium species (Gottenland et al., 2006), but others include 
Weissela confusa and Bacillus subtilis (Nam et al., 2002). The action of inhibition of H. 
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pylori by probiotics could be nonimmuologically and immunologically mediated (Lesbros-
Pantoflickova et al., 2007).  
 
Allium vegetables, particularly garlic (Allium sativum L) exhibit a broad antibiotic spectrum 
against both Gram–positive and Gram negative bacteria. It has been demonstrated in vitro 
that H. pylori is susceptible to garlic extract at a fairly moderate concentration. Even H. 
pylori antibiotic resistant strains are susceptible to garlic (Sivam, 2001). 
 
Capsaicin (hot pepper) consumed as a flavoring spice, has pharmacological, physiological 
and antimicrobial effects (Molina-Torres, 1999). Zeyrek and Oguz (2005) demonstrated in 
vitro anti-H. pylori activity of capsaicin at a concentration of 50µg/ml against metronidazole-
resistant and metronidazole-susceptible clinical isolates. There is lower ulcer prevalence in 
people consuming higher amount of pepper compared to controls. It may be advisable to 
consume raw pepper, since it is known that cooking can alter some chemical features of 
Capsicum species and by this way, their antibacterial effects may decrease (Cichewicz and 
Thorpe, 1996).  
 
Cranberry (Vaccinium macrocarpon) is a natural fruit, native to North America and 
composes of a good source of vitamin C, fructose, and bioflavonoids with anti-oxidant 
properties, which may contribute to the bacteriostatic effect of its juice. Zhang et al. (2005) in 
their preliminary study in Linqu County of Shandong Province, China, suggested that dietary 
consumption of cranberry juice may reduce H. pylori infections in adults, which remains an 
important public health issue worldwide. 
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Currently, there is renaissance of interest in the use of honey and honey products by the 
general public. This alternative branch of medicine is called apitherapy (Gosh and Playford, 
2003). Honey is the natural sweet substance produced by honey bees of the genera Apis and 
Meliponini, from nectar or blossoms or from the secretion of living parts of plants or 
excretions of plants, which they collect, transform, and combine with specific substances of 
their own to ripen and mature. It can also be defined as the nectar and saccharine exudation of 
plants, gathered, modified and stored as honey in the honeycomb by honeybees (Chauhan et 
al., 2010).  
 
Based on the source of nectar, it can be grouped into floral and non-floral honey. Honeys can 
either be unifloral or multifloral, depending whether the honey collected is from the nectar of 
the same flower or from nectar of flowers of various types. Non floral honey (honey dew) is 
made by bees that extract sugars from the living tissues of plants or fruits, and/or scavenge 
the excretions of insects (aphids) that tap the veins of higher plants (Subrahmanyam, 2007).  
 
2.6.6 An overview of honey: therapeutic properties and contribution in nutrition and 
human health. 
Because honey inherits plants properties, its color, aroma, flavor, density, and physical and 
chemical properties depend on the flowers used by bees, although weather conditions as well 
as processing also influences its composition and properties (Ramirez and Montenegro, 
2004). As a result, the nutritional values and profiles vary accordingly and can thus influence 
the value of a specific honey for health promoting purposes. Wholly, honey is made up of  
about 181 compounds  classified as carbohydrates, enzymes, amino acids, minerals, vitamins, 
 56 
 
trace elements, volatiles, and polyphenols; all of these dissolved in water (Alvarez-Saurez et 
al., 2009). Yao et al. (2003) reported that the chemical composition of honey depends on the 
floral source used to collect nectar, seasonal and environmental factors, as well as processing 
and storage conditions. 
 
2.6.6.1 Therapeutic properties of honey 
Meda et al. (2004) reported that honey is becoming acceptable as a reputable and effective 
therapeutic agent by practitioners of conventional medicine and by the general public. Its 
beneficial role has been endorsed to its antimicrobial, anti-inflammatory and anti-oxidant 
activities as well as boosting of the immune system. 
 
a) Antimicrobial activity 
The antimicrobial activity is very important therapeutically, especially in situation where the 
body’s immune response is insufficient to clear infection. In other words, it has shown 
powerful antimicrobial effects against pathogenic and non- pathogenic micro-organisms 
(yeasts and fungi) even against those that developed resistance to many antibiotics (Zaghloul 
et al., 2001). The antimicrobial effects could be bacteriostatic or bactericidal depending on 
the concentration that is used.  However, such activity has been attributed to certain factors 
like high osmolarity (low water activity), acidity (low pH), and hydrogen peroxide and non-
peroxide components (Taormina et al., 2001). 
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Furthermore, honey is a supersaturated sugar solution; these sugars have high affinity for 
water molecules leaving little or no water to support the growth of micro-organisms (bacteria 
and yeast). Consequently, the micro-organisms become dehydrated and eventually die 
(Malika et al., 2004). In addition, the natural acidity of honey will inhibit many pathogens. 
The usual pH range of most of the pathogens is around 4.0- 4.5. However, the major 
antimicrobial activity has been found to be due to hydrogen peroxide, produced by the 
oxidation of glucose by the enzyme glucose-oxidase, when honey is diluted (Temaru et al., 
2007). As hydrogen peroxide decomposes, it generates highly reactive free radicals that react 
and kill the bacteria. In most cases, the peroxide activity in honey can be destroyed easily by 
heat or the presence of catalase. 
 
Notwithstanding, some honeys have antibacterial action separate to the peroxide effect, 
resulting in a much more persistent and stable antibacterial action (non-peroxide 
activity).They are however called “non-peroxide honeys. Manuka honey (Leptospermum 
scoparium) from New Zealand and jelly bush (Leptospermum polygalifolium) from Australia 
are non-peroxide honeys which are postulated to possess unidentified active components in 
addition to the production of hydrogen peroxide. They retain their antimicrobial activity even 
in the presence of catalase (Snow and Harris, 2004). 
 
Weston (2000) suggested that the main part of this activity might be of honeybee origin, 
while part may be of plant origin. The compounds exhibiting this activity can be extracted 
with organic solvents (e.g. n-hexane, diethyl ether, chloroform, ethyl acetate) by liquid-liquid 
(Manyi-Loh et al., 2010a) or solid phase extraction methods (Aljadi and Yusoff, 2003). The 
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extracted compounds have been reported to include flavonoids, phenolic acids, volatile 
compounds (ascorbic acid, carotenoid-like substances, organic acids, neutral lipids, and 
Maillard reaction products), amino acids and proteins (Vela et al., 2007).  
 
Other important effects of honey have been linked to its oligosaccharides. They have 
prebiotic effects, similar to that of fructo oligosaccharides (Sanz et al., 2005). The 
oligosaccharides have been reported to cause an increase in population of bifidobacteria and 
lactobacilli, which are responsible for maintaining a healthy intestinal microflora in humans. 
As a matter of fact, Lactobacillus spp. protect the body against infections like salmonellosis; 
and Bifidobacterium spp restrict the over-growth of the gut walls by yeasts or bacterial 
pathogens and, perhaps reduce the risk of colon cancer by out-competing putrefactive 
bacteria capable  of liberating carcinogens ( Kleerebezem and Vaughan, 2009). 
 
b) Anti-inflammatory activity 
Although inflammation is a vital part of the normal response to infection or injury, when it is 
excessive or prolonged it can prevent healing or even cause further damage. The most serious 
consequence of excessive inflammation is the production of free radicals in the tissue. These 
free radicals are initiated by certain leucocytes that are stimulated as part of the inflammatory 
process (van den Berg et al., 2008), as inflammation is what triggers the cascade of cellular 
events that give rise to the production of growth factors which control angiogenesis and 
proliferation of fibroblasts and epithelial cells (Simon et al., 2009). 
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They can be extremely damaging and break down lipid, proteins and nucleic acids that are the 
essential components of the functioning of all cells. However, the anti-inflammatory 
properties of honey have been well established in a clinical setting (Subrahmanyam et al., 
2003) and its action is free from adverse side effects.  
 
c) Anti-oxidant activity 
Antioxidant capacity is the ability of honey to reduce oxidative reactions within the human 
body. It has been found to have a significant antioxidant content measured as its capacity to 
scavenge free radicals (Gheldof et al., 2002). This anti-oxidant activity may be at least partly 
what is responsible for its anti-inflammatory action because oxygen free radicals are involved 
in various aspects of inflammation (Henriques et al., 2006). Even when the antioxidants in 
honey do not directly suppress the inflammatory process, they can be expected to scavenge 
free radicals in order to reduce the amount of damage that would otherwise have resulted.  
 
Honey exerts its anti-oxidant action by inhibiting the formation of free radicals, catalyzed by 
metal ions such as iron and copper. Flavonoids and other polyphenols, common constituents 
of honey have the potential to impound these metal ions in complexes, preventing the 
formation of free radicals in the first place (Makawi et al., 2009). 
 
d) Boosting of the immune system 
As well as having a direct antibacterial action, honey may clear infection through stimulating 
the body’s immune system to fight infections. It has been reported that honey stimulates B-
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lymphocytes and T-lymphocytes in cell culture to multiply, and activate neutrophils (Tonks 
et al., 2003). Furthermore; Jones et al. (2000) in their study reported the stimulation of 
monocytes in cell cultures to release the cytokines TNF-alpha, IL-1 and IL-6, the cell 
“messengers” that activate the many facets of the immune response to infection. Recently, 
Tonks et al. (2007) discovered a 5.8k DA component of Manuka honey which stimulates the 
production of TNF-α in macrophages via Toll-like receptor. In addition, honey provides a 
supply of glucose, which is essential for the “respiratory burst” in macrophages that produce 
hydrogen peroxide, the dominant component of their bacteria-destroying activity (Molan, 
2001).  
 
Moreover, it provides substrates for glycolysis, the major mechanism for energy production 
in the macrophages, and thus allows them to function in damaged tissue and exudates where 
the oxygen supply is often poor. The acidity of honey may also assist in the bacteria-
destroying action of macrophages, as an acid pH inside the phagocytic vacuole is involved in 
killing ingested bacteria (Molan, 2001).  
 
2.6.6.2 Health benefits of honey 
Since ancient times, honey has been used for its medicinal properties to treat a wide variety 
of ailments. It may be used alone or in conjunction with other substances and administered 
orally or topically for the eradication of certain ailments (Williams et al., 2009). The 
beneficial actions of honey have been established in wounds, gastrointestinal diseases and 
others. In wounds, it provides a moist environment that allow skin cells to re-grow across the 
wound, stimulates the formation of new blood capillaries (angiogenesis), the growth of 
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fibroblasts that replace connective tissue of the deeper layer of the skin and produce the 
collagen fibers that give the strength to the repair as well as it provides a protective barrier 
that helps safeguard patients by preventing cross contamination (Rozaini et al., 2004). 
 
On the account of the nutritional value (303kcal/100g honey) and fast absorption of its 
carbohydrate, honey is a food suitable for humans of every age (Blasa et al., 2006). Simply, 
when orally consumed, its carbohydrates are easily digested and quickly transported into the 
blood and can be utilized for energy requirements by the human body. It is for this reason that 
honey is particularly recommended for children and sportsmen because it can help to improve 
on the efficiency of the system of the elderly and invalids (Alvarez-Saurez et al., 2009). 
 
2.6.6.2.1 H. pylori and honey  
Honey-derived remedies constitute a potential source of new compounds that may be useful 
in the management of H. pylori infections (Manyi-Loh et al., 2010b). The anti- H. pylori 
activity of honey has been demonstrated by the peroxide and non-peroxide mechanism. The 
peroxide mechanism explores factors like hydrogen peroxide, osmolarity and acidity whilst 
non-peroxide mechanism encompasses all the phytochemicals (Weston, 2000). Some of these 
phytochemicals are natural anti-oxidants and can be extractable by organic solvents (Aljadi 
and Yusoff, 2003). The amount of these components may be small or diluted in the honey but 
when extracted, they become concentrated and therefore exhibit activity. 
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Almost all organisms possess antioxidant defense and repair systems that have evolved to 
protect them against oxidative damage but insufficient to protect them entirely (Oboh, 2005). 
However, honey contains these natural anti-oxidants which exhibit a wide range of biological 
effects, including antibacterial, anti-inflammatory, anti-allergic, antithrombotic and 
vasodilatory actions (Gómez-Caravaca et al., 2006). They are reported to scavenge for free 
superoxide and other reactive oxygen metabolites liberated during respiratory burst in H. 
pylori induced mucosal damage (Li et al., 2001).  
 
Honeys from different countries and regions have a wide variability in their antimicrobial 
activity (Basson and Grobler, 2008). This is as a result of climatic variation which affects the 
distribution of flowers and plant species, from which honey bees gather nectar and sweet 
plant deposits (Ndip et al., 2007). As a result of profound heterogeneity exhibited by H. 
pylori, in combination with the regional variation in the antimicrobial components present in 
honey, there is a difference in the concentration of honey that would inhibit H. pylori in 
specific locations (Manyi-Loh et al., 2010a) 
 
2.6.6.3 Volatile phytochemicals in honey 
The non-peroxide activity of honey is usually attributed to its phytochemicals (carbohydrates, 
flavonoids, non flavonoid phenolic compounds & volatiles), which are derived from plant or 
bee origin (Yao et al., 2004). More than 600 compounds have been identified as honey 
volatiles in different chemical families, originated from various biosynthetic pathways 
(Montenegro et al., 2009). Generally, volatile organic compounds (VOCs) could be derived 
from the plant or nectar source, from the transformation of plant compounds by the 
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metabolism of a bee, from heating or handling during honey processing and storage, or from 
microbial or environmental contamination (Guyot-Declerck et al., 2002).  
 
The chemical families into which the volatile compounds in honey belong include 
hydrocarbon, aldehyde, alcohol, ketone, acid, ester, benzene and its derivatives, furan and 
pyran derivatives, norisoprenoids, terpenes and its derivatives and sulphur and cyclic 
compounds (Barra et al., 2010). Though present in low concentration in honey, VOCs could 
contribute in the biomedical activities of honey especially antioxidant effect due to their 
natural radical scavenging potential. For example, ascorbic acid, hydroxymethylfufural 
(HMF) and maillard reaction products have been reported to demonstrate antioxidant activity 
and also other compounds such as terpenes, organic acids, benzene derivatives and carotenoid 
have presented potential antimicrobial as well as antioxidant activities (Turkmen et al., 2006; 
Jerković et al., 2010). 
 
Aside the beneficial therapeutic properties of volatile compounds, they could be used to 
assess the botanical/floral origin of honey as well as in determining the aroma profile. 
Knowledge about the floral origin of a honey will help to prevent fraud, standardize its 
quality and authenticate the honey thus allowing it to be competitive in the market (Castro-
Várquez et al., 2010). 
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CHAPTER THREE 
SELECTED SOUTH AFRICAN HONEYS AND THEIR SOLVENT EXTRACTS 
POSSESS IN VITRO ANTI- HELICOBACTER PYLORI ACTIVITY 
ABSTRACT 
The growing problem of antibiotic resistance by Helicobacter pylori demands the search for 
novel compounds, especially from natural sources. The anti-H. pylori activity of six local honeys 
Pure Honey (PH), Citrus Blossom (CB), Goldcrest (GC), Champagne Royal Train (CRT), 
Honeyleine (HL) & Heritage (HH)) at four different concentrations [10, 20, 50 & 75 (% v/v)]  as 
well as their solvent extracts (n-hexane, diethyl ether, chloroform & ethyl acetate) were 
evaluated by agar well diffusion method. The minimum inhibitory concentration (MIC50) of the 
two most active extracts of each honey was determined by the broth microdilution technique and 
absorbances were recorded by ELISA microtitre plate reader adjusted at 620nm. Data were 
analyzed by one-way ANOVA test at 95% significance level. All the honey varieties as well as 
their solvent extracts demonstrated varying levels of antibacterial activity based on different 
mean zone diameters [16.0mm (crude) to 22.2mm (extract)] and percentage susceptibilities 
[73.3% (crude) to 93.3% (extract)] of the test isolates. The chloroform extracts of PH and CRT 
recorded MIC50 ranges of 0.01-10% and 0.625-10 % (v/v) respectively; that were not 
significantly different (P > 0.05) from amoxicillin (0.001-1.25mg/mL), the positive control. In 
conclusion, all honeys demonstrated anti-H. pylori activity at concentrations ≥ 10%, so also did 
the solvent extracts. Therefore, these honeys and solvent extracts possess potential compounds 
with therapeutic activity which could be exploited further as lead molecules in the treatment of 
H. pylori infections. 
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  3.1 INTRODUCTION 
Helicobacter pylori (H.pylori) is a curved or s-shaped gram-negative, non-capsulated, non-spore 
forming bacillus (Ghany, 2005) that infects at least 50% of the world’s human population 
(Czinn, 2005). It is incriminated as the main aetiological agent of gastritis (Módena et al., 2007); 
an essential factor in the pathogenesis of peptic ulcer as well as a risk factor in the genesis of 
gastric carcinoma and mucosa associated lymphoid tissue (MALT) type gastric lymphoma 
(Roszczenko and Jagusztyn-Krynicka, 2006). The significance of these infections and the need 
for effective therapeutic agents have  led to the development of several drug treatment regimens 
including dual, triple and quadruple therapy.  
 
However, the first line regimen for eradication of the organism includes a triple therapy, which 
combines two known antibiotics (clarithromycin or amoxicillin and metronidazole) with a proton 
pump inhibitor (Mégraud and Lehours, 2007). Nevertheless, because triple therapy fails to 
eradicate infection in 10-20% of patients, quadruple therapy was introduced as a new treatment 
modality as well as a rescue treatment for antibiotic-resistant strains of H. pylori (Suerbaum and 
Michetti, 2002).  
 
Although, most of these therapeutic modalities are approximately 90% effective, they are usually 
associated with high levels of antibiotic resistance (Ndip et al., 2008; Tanih et al., 2010a), 
undesirable side effects (diarrhea, nausea, abnormal taste, dyspepsia, abdominal pain/discomfort, 
and headache), poor patient compliance (Bytzer and O’Morain, 2005), high cost, unavailability 
of antibiotics especially in rural areas and the pH of gastric juice, an important factor that 
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potentially affects drug activity (Malekzadeh et al., 2004). These therefore, result in significant 
levels of treatment failure and contraindications for some patients. 
 
Accordingly, there is a strong demand for compositions with beneficial properties of current 
therapeutic agents that could achieve eradication of the bacterium with minimal side effects, at 
reduced cost, without the risk of resistance and improved efficacy of the therapy. Antimicrobial 
substances other than antibiotics would be very useful in the treatment of H. pylori infections if 
they are shown to be effective against both the antibiotic-resistant and susceptible strains. Over 
the years, there has been a lot of interest in the investigation of natural products as sources of 
new antibacterial agents (Shmuely et al., 2007).  
 
Several natural products have demonstrated in vitro antibacterial activity against H. pylori 
(Lesbros-Pantoflickova et al., 2007; Ndip et al., 2008; Njume et al., 2011). The vast amount of 
data about honey's therapeutic properties, along with the rapidly increasing interest in and 
research into natural health remedies and supplements, has led to a resurgence in interest in 
honey's therapeutic uses. Honey-derived remedies constitute a potential source of new 
compounds that may be useful in the management of H. pylori infections. Honey has been 
recognised for its medicinal properties since antiqiuty (Namias, 2003). It has been shown to be 
active against a diverse range of micro-organisms including Gram positive and negative 
organisms, aerobic and anaerobic bacteria (Zaghloul et al., 2001; Ndip et al., 2007), and Candida 
albicans as well as inhibiting the germination of the spores of Bacillus cereus (El-Toun and 
Yagoub, 2007).  
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The principal antibacterial factor has been reported to be hydrogen peroxide produced by the 
oxidation of glucose by the enzyme glucose oxidase, which is activated by successive dilutions 
of honey (Iurlina and Fritz, 2005). Other antimicrobial factors include its osmolarity, acidity, low 
protein content and non-peroxide components (Malika et al., 2004). These non-peroxide factors 
(flavonoids and phenolic acids) are derived from plant origin. The amount of these components 
may be small or diluted in the honey but when extracted with organic solvents (Aljadi and 
Yusoff, 2003); they become concentrated and therefore exhibit more activity. Flavonoids, 
phenolic and organic acids in honey are known to scavenge for free superoxide and other 
reactive oxygen metabolites liberated during respiratory burst in H. pylori induced mucosal 
damage (Li et al., 2001). 
 
Honeys from different countries and regions have a wide variability in their antimicrobial 
activity, as a result of different vegetative flowers and plant species blooming in different 
seasons (Ndip et al., 2007; Basson and Grobler, 2008; Manyi-Loh et al ., 2010). Interestingly, 
South Africa has a large floral biodiversity with many unique plants indigenous to the region, 
from which various honeys are being produced. The inhabitants of the country consume these 
honeys with the belief that it boosts the immune system and is good for wound healing and 
stomach ailments. In the Eastern Cape Province of the country, the ‘Xhosas’ use their honeys to 
produce” iqhilika” (Mead), which is a cultural wine and is said to be of great medicinal value and 
can be used in the treatment of  coughs, kidney  and stomach ailments. 
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In addition, H. pylori has been reported to be prevalent and multidrug resistant strains are present 
in the study area (Tanih et al., 2010a), a situation which merits attention. In spite of the wide 
body of research on the antibacterial activity of honey against several medically important 
pathogens including H. pylori, in different parts of the world, there is paucity of information, on 
the possible antibacterial activity of South African honeys against H. pylori. 
 
Consequently, this study was designed to screen South African honey varieties and their solvent 
extracts for anti-H. pylori activity and to determine the minimum inhibitory concentration 
(MIC50) of the two most active extracts of each honey. 
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3.2 MATERIALS AND METHODS 
3.2.1 Bacterial strains 
A total of thirty clinical isolates of H. pylori were employed which were recovered from gastric 
biopsies obtained from patients presenting with gastro duodenal pathologies at Livingstone 
Hospital, Port Elizabeth, South Africa. This was done after informed consent was obtained as per 
previously reported schemes (Ndip et al., 2008; Tanih et al., 2010b). Confirmed isolates were 
stored in Brain Heart Infusion broth + 20% glycerol at -80oC for subsequent bioassays. H. pylori 
ATCC (American Type Culture collection) 43526 was used as the control strain.  
 
3.2.2 Source and dilution of honey 
In this study, six honey varieties obtained from different floral sources and localities in South 
Africa were used (Table 3.1). To the best of my knowledge, these honeys were raw, not 
processed. Different concentrations of each honey constituting, 10% v/v, 20% v/v, 50% v/v and 
75% v/v were made in sterile distilled water. This was done by dissolving the respective 
volumes: 0.1mL, 0.2mL, 0.5mL, 0.75mL of each honey into corresponding volumes of sterile 
distilled water to give a 1mL final volume. The different dilutions of each honey were sterilized 
by filtering through a 0.22µm membrane filter (Acrodisc, Pall Corporation, USA) (Al-Somal et 
al., 1994) into separate sterile bijou bottles.    
 
 
 
 97 
 
Table 3.1: Floral sources of honeys and their geographical locations 
 
Honey types  Floral source Physical property 
(color) 
Geographical     
Location 
Pure honey(PH) 
 
Citrus Dark brown Eastern cape 
Goldcrest (GC) 
 
Citrus Dark brown Gauteng  
Champagne  
royal train (CRT) 
 
Vineyards Dark brown Western cape 
Honeyleine (HL) 
 
Strawberries Dark brown KwaZulu Natal  
Heritage (HH) Eucalyptus, fynbos, 
wildflower 
Dark brown Western Cape. 
Citrus blossom (CB) Berry orchards Pale brown Western Cape 
 
3.2.3 Antibacterial screening of honey varieties  
The agar well diffusion method was adopted according to the method of Dastouri et al. (2008) to 
assess the antibacterial activity of the crude honeys. Brain Heart Infusion(BHI) agar (Oxoid, UK) 
was prepared following the manufacturer’s instructions, supplemented with 7% laked horse 
blood (Oxoid, England) and Skirrow’s antibiotics (SR 0147E, Oxoid, UK).  An inoculum of each 
clinical strain was prepared from a subculture of bacterial suspension and the turbidity adjusted 
to 1.8 x 108 CFU/mL (corresponding to 0.5 McFarland standards). A sterile cotton swab was 
dipped into the standardized bacterial suspension and used to evenly inoculate the BHI agar 
plates. The plates were allowed to dry for 3-5 minutes.  
 
Five wells were cut in each agar plate with a flamed, cooled, cork borer of 6mm diameter, and 
the agar plugs removed with a sterile needle. One hundred µL of the different concentrations of 
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each honey was dispensed separately into each well, in each plate. Clarithromycin (0.05μg/mL) 
was used as the positive control.  The plates were incubated at 37ºC for 2-5 days under 
microaerophilic conditions (CampyGen BR0056A, Oxoid, UK). Three replicates were carried 
out for each strain. After incubation, plates were examined and the diameters (in millimetres) of 
the zones of inhibition were measured not including the diameter of the well, averaged and the 
mean values recorded. H. pylori control strain ATCC 43526 was included in all the experiments. 
 
3.2.4 Solvent extraction of crude honey 
 Observing that the percentage susceptibilities of the test isolates to honey varieties were greater 
than 50 based on zone diameter ≥ 14mm, all honeys (except Heritage honey and Citrus Blossom)  
were extracted using different organic solvents. This was done using the method of Zaghloul et 
al. (2001) with modifications. One hundred grams of crude honey was placed in a 500mL 
separating funnel, diluted with 150mL of sterile distilled water and extracted with 150mL of the 
different organic solvents (n-hexane, diethyl ether, chloroform and ethyl acetate). This was 
performed as three successive extractions using 50mL of solvent each time.  
 
The shaking time for each extraction process was 15minutes, after which the mixture was 
allowed to stand to permit the solvent layer to separate. The three successive layers were 
collected, mixed and concentrated by evaporation under reduced pressure using a rotary 
evaporator (Steroglass, Strike 202, Padua, Italy) at 40oC for n-hexane, 30oC for diethyl ether, 
50oC for chloroform, and 60oC for ethyl acetate.Water contaminating layers was removed by 
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Fig.3.1. A flow chart for solvent extraction of honey                                                                      
filtration over anhydrous sodium sulphate. The complete extraction plan is as shown on the flow 
diagram (Fig.3.1). 
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3.2.5 Antimicrobial susceptibility testing of honey solvent extracts. 
The different solvent extracts of each honey at its most active concentration (50% v/v for CRT, 
HL; 75% v/v for PH, GC) were tested against the isolates using the method described for crude 
honey above. The respective pure solvent used for the extraction was tested side by side with its 
extract. Diameters of zones of inhibition of extracts were measured; averaged and mean values 
recorded in millimeters. 
 
3.2.6 Determination of the minimum inhibitory concentration (MIC50) 
The two most active extracts of each honey were employed in broth microdilution assay to 
determine their MICs against the test isolates, according to the method of Njume et al. (2011). 
Two-fold dilutions were prepared in 96-well-round-bottom microtitre plates (Greiner Bio-One, 
Frickenhausen, Neuburg, Germany) in BHI broth (Oxoid, England); the final extract 
concentration was 0.01-10%v/v. Similarly, amoxicillin (0.0012 - 1.25 mg/mL) and 
metronidazole (0.01-10 mg/mL) were two-fold diluted and tested on the same plate with the 
honey solvent extracts as reference antimicrobials. Control wells were also prepared with culture 
medium only, culture medium with honey extract and culture medium with bacterial isolate only.  
 
The inoculum of each strain was diluted tenfold in sterile normal saline. Twenty µL of the 
bacterial suspension (108 CFU/mL) was aliquoted into each well. The final volume in each well 
of BHI broth, honey extract, and inoculum was 120µL. The absorbencies were read using an 
ELISA microtitre plate reader (Model 680, S/N 19138, Biorad, Japan) adjusted at 620nm. The 
micro plates were sealed and incubated at 37oC under microaerophilic conditions for 2-3days, 
 101 
 
agitated and the absorbencies were again read at the same wavelength. The absorbencies were 
compared to the values obtained before incubation to detect any increase or decrease in bacterial 
growth. The lowest concentration of the extract resulting in inhibition of bacterial growth by 
50% was taken as the MIC50.  
 
 
3.2.7 Statistical analysis 
Diameters of zones of inhibition (excluding the diameter of the well) were expressed as mean ± 
standard deviation using Excel. One-way ANOVA test was used while employing SPSS (version 
18.0, Illinois, USA) to determine any statistically significant difference by comparing zone 
diameters of the different honeys at various concentrations; zone diameters of clarithromycin to 
different solvent extracts, zone diameters of different extracts as well as the MIC values of these 
extracts to amoxicillin and metronidazole at 95% significance level. 
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3.3 RESULTS 
3.3.1 Antibacterial screening of honey varieties  
All the honey samples at the various concentrations (10, 20, 50, 75%v/v) exhibited varying 
levels of antibacterial activity against the test isolates as indicated by mean ± S.D of zone of 
inhibition and percentage susceptibilities (Table 3.2).The susceptibilities of the isolates to the 
honey varieties are shown on figure 3.2. PH, CB and GC honeys were most active at 75% v/v 
concentration whilst CRT, HL and HH were most active at 50% v/v concentration. 
Consequently, there was no statistically significant difference (P > 0.05) recorded when the mean 
zone diameters of these honeys obtained at their most active concentrations were compared to 
that of clarithromycin (positive control).  
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Table 3.2: Analysis of the anti-Helicobacter pylori activity of honey varieties by agar well 
diffusion  assay 
Honey types             Zones of inhibition (mm) a and Percentage susceptibility (%)  
 
                              Concentrations of honey(% v/v) 
             10             20             50               75 
Pure honey(PH) 
 
Citrus blossom 
(CB)      
 
12.0 ± 8.9 
16/30(53.3) 
13.3 ± 7.5                  
17/30 (56.7) 
13.3 ± 7.8 
19/30 (63.3) 
12.6 ± 8.0 
17/30 (56.7) 
12.7 ± 9.9 
16/30(53.3) 
15.1 ± 8.7 
20/30 (66.7) 
16.0 ± 7.5 
22/30 (73.3) 
15.5 ± 8.5 
21/30 (70.0) 
Goldcrest(GC)  13.3 ± 7.8 
18/30(60.0) 
12.9 ± 7.9 
16/30(53.3) 
14.4 ± 9.0 
18/30(60.0) 
13.7 ± 10.0 
20/30(66.7) 
Champagne  
royal train(CRT) 
11.0 ± 8.6 
16/30 (53.3) 
12.5 ± 9.1 
15/30 (50.0) 
12.7 ± 8.6 
17/30 (56.7) 
16.0 ± 7.4 
16/30 (53.3) 
Honeyleine(HL) 11.0 ± 8.7 
14/30 (46.7) 
11.7 ± 8.5 
17/30 (56.7) 
13.0 ± 9.2 
19/30 (63.3) 
14.8 ± 8.6 
18/30 (60.0) 
Heritage(HH) 11.6 ± 9.2 
16/30 (53.3) 
12.4 ± 8.4 
17/30 (56.7) 
13.1 ± 9.2 
18/30 (60.0) 
15.1 ± 6.1 
16/30 (53.3) 
Clarithromycin 
(CLR);0.05µg/mL 
                                               18.0 ±7.3 
                                             23/30(76.7) 
 a mean of triplicate assay ± standard deviation; Zone of sensitive isolate ≥ 14mm. 
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Fig.3.2: Antimicrobial activity of honey varieties at 10% v/v, 20% v/v, 50% v/v, 75% v/v    
against H. pylori isolates. Zone diameters of sensitive isolates were ≥ 14. 
 
3.3.2 Antimicrobial susceptibility testing of honey solvent extracts 
All the solvent extracts of the honeys demonstrated anti-H. pylori activity with mean zone 
diameter of inhibition and percentage susceptibility of isolates in the ranges 14.5- 22.2 mm and 
53.3-93.35% respectively (Table 3.3). Based on the percentage susceptibility and mean zone 
diameter of inhibition, diethyl ether extract of CRT honey was the most active (22.2 ± 6.1mm; 
28/30, 93.3%) while the least antibacterial activity was noted for n-hexane extract of PH honey 
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(15.8±7.9mm; 16/30, 53.3%). However, no statistically significant difference (P> 0.05) was 
reached comparing the mean zone diameters of solvent extracts to clarithromycin. 
 
Table 3.3: Analysis of the anti-Helicobacter pylori activity of solvent extracts by agar well 
diffusion assay  
Honey types                   Zones of inhibition (mm) a and Percentage susceptibility (%) 
                                        Solvent extracts of honey varieties 
n-Hexane Diethyl ether Chloroform Ethyl acetate 
Pure honey(PH) 15.8 ± 7.9 
16/30 (53.3) 
18.8 ± 8.3 
21/30 (70) 
16.9 ± 6.6 
19/30 (63.3) 
16.3 ± 7.6 
18/30 (60.0) 
Goldcrest (GC) 17.9 ± 8.7 
19/30 (63.3) 
19.9 ± 10.1 
22/30 (73.3) 
15.2 ± 8.7 
17/30 (56.7) 
16.7 ± 9.3 
18/30 (60.0) 
Champagne royal 
train (CRT) 
18.5 ± 6.6 
25/30 (83.3) 
22.2 ± 6.1 
28/30 (93.3) 
21.2 ± 6.4 
27/30 (90.0) 
16.2 ± 8.6 
23/30 (76.7) 
Honeyleine (HL) 14.5 ± 9.3 
20/30 (66.7) 
17.9 ± 11.0 
20/30 (66.7) 
15.9 ± 9.1 
19/30 (63.3) 
17.5 ± 8.9 
22/30 (73.3) 
Clarithromycin 
(CRT);0.05µg/mL 
                                              18.0 ±7.3 
                                             23/30(76.7) 
  a mean of triplicate assay ± standard deviation; Zone of sensitive isolate ≥ 14.
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3.3.3 Determination of the minimum inhibitory concentration (MIC50) 
Inhibitory-zone testing is the primary method for evaluation of the susceptibility of the test 
isolates to honey solvent extracts. Given the relatively low sensitivity of this method, MIC 
testing was used as complementary method to evaluate the antibacterial activity of the solvent 
extracts. The MIC50 values of all the extracts ranged from 0.01-10% v/v concentration (Table 
3.4). The two most active extracts were the chloroform extract of PH and CRT honeys with 
MIC50 ranges of 0.01-10% v/v and 0.625-10% v/v respectively; since there was no 
statistically significant difference (P > 0.05) recorded when their MIC50 values were 
compared to amoxicillin (0.001-1.25mg/mL), the most sensitive antibiotic in the local 
treatment regimen. The ethyl acetate extract of HL and n-hexane extract of GC honeys 
recorded MIC50 values of 0.156-10% v/v and 0.039-10%v/v respectively. 
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Table 3.4:  MICs of the two most active extracts of each honey and reference antimicrobials at 50% bacterial growth inhibition 
H. 
pylori 
isolates 
                                                          MIC50 values in different concentrations 
                                                       Concentrations of solvent extracts (%v/v) Antibiotics (mg/mL) 
Pure Honey(PH) Champagne (CRT) Honeyleine (HL) Goldcrest (GC) Amoxicillin Metronidazole 
  CHLOE          DEE CHLOE         DEE EAE            DEE n-HEX       DEE AMOX MET 
PE11A - - - - - - - - 0.039 5 
PE11C - - - - - - 5 5 0.078 5 
PE26A - - 1.25 - - - - - 0.02 5 
PE76A 1.25 10 10 - - - - - 0.039 5 
PE84C - - - 10 1.25 - 10 - 0.01 2.5 
PE93A 1.25 1.25 0.625 0.625 - 0.625 5 5 0.625 5 
PE102C 10 - - - 10 - - 10 0.039 5 
PE115A 10 - - - 10 - 10 - 0.02 5 
PE162C - - - - 5 - 5 5 0.001 5 
PE219C 10 1.25 0.625 0.625 2.5 1.25 - - 0.625 5 
PE252C 1.25 - 10 10 2.5 - 2.5 1.25 0.039 5 
PE258C 1.25 2.5 2.5 2.5 - 1.25 - - 0.313 10 
PE308C 1.25 10 - 10 2.5 - 2.5 1.25 0.078 5 
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PE369A 1.25 1.25 1.25 1.25 - 1.25 - - 0.039 5 
PE369C - - - 10 0.625 - 10 0.625 0.02 5 
PE397C 1.25 - - - 1.25 10 5 5 0.625 5 
PE406C 2.5 10 - 10 10 - 5 1.25 0.156 5 
PE407C - 10 - 10 - - - - 0.313 5 
PE411C - 1.25 1.25 1.25 - 1.25 - - 0.039 5 
PE430A 10 - - 10 - - 2.5 - 0.01 5 
PE430C - 10 - 10 0.156 - - 0.078 0.039 5 
PE435A 2.5 1.25 1.25 1.25 - 1.25 - - 0.039 5 
PE436A      - 0.625 0.625 0.625 2.5 1.25 1.25 1.25 0.625 5 
PE462A - - - - - - 0.039 - 0.625 5 
PE462C - - 0.625 - - 10 - - 1.25 2.5 
PE464A - 10 - 10 10 - - - 0.078 5 
PE464C 1.25 - - - 2.5 10 1.25 1.25 0.002 2.5 
PE466A 10 - - - 10 - 10 10 0.01 5 
PE466C 0.01 - - - - - - - 0.625 5 
PE473A 2.5 - - 10 2.5 - 2.5 2.5 0.156 5 
MIC50 after triplicate assay; -, value not within susceptible range; CHLOE, chloroform; DEE, diethyl ether;  HEX, hexane; EAE, ethyl acetate; 
AMOX,amoxicillin;MET,metronidazole.
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3.4 DISCUSSION 
The indiscriminate use of antibiotics has developed many resistant micro-organisms creating 
immense clinical problems in the treatment of infectious diseases such as those caused by H. 
pylori. Therefore, there is a need to develop alternative antimicrobial agents for the treatment 
of these infectious diseases. A non-antibiotic approach to the treatment and prevention of 
these infections includes the application of honey. Honey is produced from many different 
floral sources and its antimicrobial activity varies with origin and processing (Weston, 2000). 
Considering the enormous potential using honey in a clinical setting, it is important that 
research continue not only using honeys that are commercially available but also those of 
local origin with a dearth of information on their antimicrobial potential. 
 
Therefore, in the preliminary screening of PH, CB, GC, CRT, HL and HH honeys at various 
concentrations (10, 20, 50 and 75% v/v), the data showed that these honeys possess anti-H. 
pylori activity exhibited by zones of inhibition that ranged from 11.0-16.0 mm. This 
inhibition gives credence to the fact that these honeys could be used as antibacterial agents in 
the treatment of ailments caused by H. pylori. 
 
Furthermore, this result is congruent with the work of Saraf and colleagues (2009) that 
evaluated the antibacterial activity of local Fijian honeys on both gram- positive and gram- 
negative bacteria at varying concentrations. With the exception of the other three honeys, the 
anti-H. pylori activity of PH, CB and GC honeys was concentration dependent since they 
were most active at 75% v/v concentration (Fig.3.2). In addition, there was no statistically 
significant difference (P > 0.05) recorded when the mean zone diameters of these local 
honeys at their most active concentrations were compared to that of clarithromycin. This may 
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advocate that these honeys at their specified concentrations could elicit antibacterial potential 
seeming that of clarithromycin, a key antibiotic in H. pylori treatment regimen (Megraud and 
Lehours, 2007). 
 
In spite of the fact that all the honeys demonstrated antibacterial activity against the test 
isolates, there was variation in the percentage susceptibilities of the isolates to the different 
honey types (Fig.3.2). This discrepancy in the observed antibacterial activity could be due to 
several reasons. One possibility might be related to the differences in susceptibility of each 
isolate to the honey used, since the pathogen is said to exhibit considerable genetic 
heterogeneity, therefore no two strains are identical (Logan and Walker, 2002).  
 
Moreover, the variable results observed between honeys has purportedly been attributed to 
different floral sources and plant species utilized by the bees and geographical factors like 
temperature, humidity where the honeys were produced (Nzeako and Hamdi, 2000; Ndip et 
al., 2007). Apparently, the environmental conditions would influence the chemical 
composition of the honeys and as a consequence their biological properties/functions would 
differ. This may hold true for this study since the honeys were obtained from different floral 
sources and localities in South Africa. 
 
Other possible explanation for these observations could be the differences in putative 
antibacterial agent(s) present in these honeys (Tumin et al., 2005). These agents may utilize 
hydrogen peroxide and non-peroxide antioxidant component. As reported by others (Melissa 
et al., 2004; Ndip et al., 2007) dilution of honey enhances hydrogen peroxide mediated 
antibacterial activity which may explain the discrepancies observed with the antibacterial 
activity of these honeys because its  concentration is determined by the relative levels of 
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glucose oxidase synthesized by the bee and catalase obtained from plant pollen (Weston, 
2000).  
 
The non-peroxide factors of honeys include volatile compounds, phenolic acids and 
flavonoids (phytochemicals). The accumulation of these phytochemicals depends on climatic 
conditions (sunlight, moisture), soil characteristics and other factors; therefore it is logical to 
have disparity in the antibacterial activity between the honeys types due to differences in the 
composition of pollen or nectar, which have greatest influence on the chemical composition 
of these honeys (Kaškonienė and Venskutonis, 2010). 
 
In the past, several studies have reported the antimicrobial activity of only the aqueous 
solution of honey (Taormina et al., 2001; French et al., 2005; Ndip et al., 2007). It is obvious 
that honey possesses antimicrobial potential but it is not clear whether it is the mass of the 
honey or some fraction of it. In view of the fact that there might be some specific components 
(phytochemicals or non-peroxide factors) such as flavonoids, volatile compouds and phenolic 
acids which may be contributing to the antimicrobial activity, four organic solvents viz n-
hexane, diethyl ether, chloroform and ethyl acetate that have been previously employed by 
Zagloul et al. (2001) to possibly extract the afore mentioned phytoconstituents were used.  
 
Accordingly, PH, GC, CRT and HL honeys were employed in the extraction process except 
HH and CB honeys that were obtained from the same locality as CRT honey. The physical 
properties (particularly color) credited the continued usage of CRT honey in the subsequent 
bioassays. The color of honey is closely related to its chemical composition, primarily to the 
presence of carotenoids, flavonoids and derivatives of tannins and polyphenols (Kaškonienė 
et al., 2009). Moreover, Yao et al. (2003) reported that the antimicrobial potential of honey 
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could be ascribed to its chemical composition. The solvent extracts of the honeys were 
evaluated for anti-H. pylori activity. The resulting data showed that the most potent 
antibacterial activity against the test isolates was demonstrated by the diethyl ether extract of 
CRT honey (22.2 ± 6.1mm; 28/30, 93.3%) unlike the n-hexane extract of PH honey (15.8 ± 
7.9 mm; 16/30, 53.3%) that presented the least antibacterial activity. This was based on mean 
± S.D of zone diameter of inhibition observed with each solvent extract as well as the 
percentage susceptibilities of the test isolates to each extract (Table 3.3). 
 
 Notwithstanding, all the solvent extracts presented good anti-H. pylori activity implying that 
these honeys may contain a diverse range of bioactive components which were extractable 
into the various solvent extracts. This corroborates the finding of Chauhan et al. (2010) that 
equally reported significant antibacterial activity of solvent extracts of honey against gram 
negative micro-organisms. In addition, there was no statistically significant difference (P > 
0.05) recorded when the mean ± S.D of diameters of zones of inhibition were compared to 
the positive control (clarithromycin); suggesting that the specific solvent extracts may contain 
putative antimicrobial compounds whose therapeutic potential are highly comparable  to 
clarithromycin.  
 
Furthermore, we realized an increase in the antimicrobial activity of the solvent extracts of 
these honeys. Based on mean zone diameter and percentage susceptibilities of test isolates, 
there was an increase from 16.0mm (crude) to 22.2mm (extracts) and 73.3% (crude) to 93.3% 
(extract) respectively. It is noteworthy that the diameter of zone of inhibition was considered 
as a measure of antibacterial activity. Therefore, the larger the zone of inhibition, the more 
active or the greater the activity of the product (Manyi-Loh et al., 2011). These results 
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suggest that there was an increase in antibacterial activity of honey after extraction, 
insinuating the putative antibacterial agents might have been isolated from the bulk of honey.  
 
In the assay to determine MIC50 of the two most active extracts of each honey, amoxicillin 
and metronidazole were employed as reference antimicrobials. The assay indicated that the 
MIC50 values varied with extracts and the isolates (Aljadi and Yusoff, 2003). This variation 
could be attributed to putative components present in the different extracts. The lowest MIC50 
range (best antibacterial activity) of 0.01-10% was obtained for the chloroform extract of PH 
honey.  
 
Both the ethyl acetate extract of HL and n-hexane extract of GC honeys recorded MIC50 
values of 0.156-10% v/v and 0.039-10%v/v respectively. In addition, no statistically 
significant difference (P> 0.05) was recorded when MIC50 values of the chloroform extracts 
of PH (0.01-10%v/v) and CRT (0.625-10%v/v) honeys were compared to amoxicillin (0.001-
1.25mg/mL). This may suggest that of the four solvents used for extraction in this study, 
chloroform extracts demonstrated the highest relative antibacterial activity; advocating that 
chloroform solvent might have had higher solubility for antimicrobial phytoconstituents 
because it has been reported that different solvents have the capacity to extracts different 
phytoconstituents based on their solubility or polarity (Doughari, 2006). This may further 
indicate that these chloroform extracts would contain most active substances (Yeşilada et al., 
1999). 
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3.5 CONCLUSIONS 
The results of this study unequivocally shows that PH, GC, CRT and HL honeys (bulk 
components) as well as the necessary antibacterial components extracted in n-hexane, diethyl ether, 
chloroform and ethyl acetate solvents from these honeys could become  potential candidates to be 
exploited for further investigation in the discovery of novel natural anti-H. pylori compounds, 
which would be useful on a sustainable basis.  
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CHAPTER FOUR 
BACTERICIDAL ACTIVITY OF SOLVENT EXTRACTS OF SELECTED 
SOUTH AFRICAN HONEYS AGAINST CLINICAL 
ISOLATES OF HELICOBACTER PYLORI 
 
ABSTRACT 
The growing resistance of Helicobacter pylori (H. pylori) to antibiotics used in its treatment 
as well as other inherent limitations of the triple therapy has brought forth the quest for 
alternative treatment from natural sources. Apitherapy has shown promising effects as an 
alternative source of H. pylori treatment. In this light, selected South African honeys and 
their solvent extracts have demonstrated considerable anti-H. pylori activity. Therefore, in 
this study the most active solvent extracts of each honey; chloroform extracts of Pure Honey 
(PH) and Champagne Royal Train (CRT) as well as the n-hexane and ethyl acetate extracts of 
Goldcrest (GC) and Honeyleine (HL) honeys respectively were evaluated for their 
bactericidal activity against H. pylori strains. The time kill assay of the most active extracts 
was determined by viability studies over a period of 72hrs. The most potent bactericidal 
effect against the test isolates was obtained with 5% v/v (1/2 MIC) concentration of 
chloroform extract of PH from 36-72hrs. Notwithstanding, the other three solvent extracts 
were most bactericidal at 40% v/v (4MIC) at different time intervals. In conclusion, these 
honeys and their extracts may contain compounds with anti-H. pylori activity and therefore 
calls for more elaborate phytochemical studies to isolate and characterize the compounds. 
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4.1 INTRODUCTION 
Helicobacter pylori (H. pylori), has probably been part of the human gastric biota since time 
immemorial (Blaser, 1997). It is a human pathogen, which is directly associated with many 
diseases of the upper gastrointestinal tract including acute and chronic gastritis, non-ulcer 
dyspepsia, peptic ulcer disease (gastric and duodenal ulcers), and gastric cancers 
(Williamson, 2001). It is a major public health concern, since these diseases are major causes 
of death worldwide. Eradication of this pathogen is now a major step in the therapeutic 
management of the above mentioned diseases (Beasles, 2001). 
 
Conventional treatment of H. pylori infection is principally based on the use of triple 
therapies consisting of a combination of two antibiotics (clarithromycin, amoxicillin, and/or 
metronidazole) with a proton pump inhibitor (Mégraud and Lehours, 2007). Unfortunately, 
H. pylori is capable to develop drug resistance after a period of repeated use of these drugs 
especially at suboptimal levels (Matsumoto et al., 1997). Such resistant strains are becoming 
problematic worldwide (Ochi et al., 2005) and may lead to high failure rates of treatment 
regimens. In addition, non-compliance of patients to the treatment regimen as well as side 
effects of the drugs may also result in eradication failure. These necessitate the search for 
new chemotherapeutic agents with excellent activity, which hopefully can eradicate the 
pathogen. 
 
Honey is among the attractive sources that has received attention as an alternative treatment 
for H. pylori infections. Apitherapy or therapy with bee products is an age-old therapeutic 
practice as recorded by several ancient civilizations. Honey is a natural sweet substance, 
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produced by bees from plant nectars, plant secretions and excretion of plant sucking insects 
(Williams et al., 2009). It is a supersaturated sugar solution containing vitamins, minerals, 
proteins, amino acids and nutrients. The largest portion of it as dry matter consists of sugars 
(79%), which are responsible for much of its physical nature, viscosity, hygroscopicity and 
energy content (Ansari and Alexander, 2009). The therapeutic effects of honey have been 
ascribed to its antimicrobial, anti-inflammatory and anti-oxidant properties.  
 
Honey has shown powerful antibacterial effects against pathogenic and non-pathogenic 
micro-organisms, yeast and fungi even against those that developed resistance to many 
antibiotics (Molan and Cooper, 2000; Manyi-Loh et al., 2010). Its sugars exert strong 
osmotic potential attracting water molecules and as such inhibit the growth of bacteria and 
fungi. In addition, it contains the enzyme glucose oxidase, which acts on glucose in the 
presence of water, producing hydrogen peroxide and gluconic acid. Hydrogen peroxide is the 
major contributor to the antimicrobial activity of honey, and the different concentrations of 
this compound in different honeys result in their varying antimicrobial effects (Molan, 1992). 
 
Furthermore, antioxidants and flavonoids that may function as antibacterial agents are also 
present. The pH of honey is low and ranges from 3.2 to 4.5 with the most predominant proton 
donor being gluconic acid. In light of modern science, several important therapeutic effects of 
honey have been elucidated (Cooper et al., 2002) and these vary with the quality of the honey 
produced. The type of honey produced is dependent on the flowers blooming in different 
seasons, in different regions and countries (Ndip et al., 2007). Consequently, there is 
variation in the chemical composition as well as the physical properties of honey. As a result, 
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micro-organisms differ in their sensitivity to honeys collected from different sources, regions 
and countries.  
 
Pure honey has demonstrated bactericidal activity against many enteropathogenic organisms, 
including those of the Salmonella and Shigella species, and enteropathogenic E. coli (Molan, 
2001). In vitro studies suggested that honey possesses bactericidal activity against H. pylori 
(Al-Somal et al., 1994; Ndip et al., 2007).  Even isolates that exhibited resistance to other 
antimicrobial agents were susceptible to honey (Ali et al., 1999). The antibacterial action of 
honey could be bacteriostatic (inhibitory) or bactericidal (killing) (Osman et al., 2003). 
 
Based on the promising or considerable activity (inhibitory) presented by the solvent extracts 
in  the previous study, it is therefore necesssary to evaluate the bactericidal activity of the  
most active solvent  extract of each honey type (PH, CRT, GC& HL). Consequently, this 
study was designed to ascertain the rate of kill of H. pylori strains by the chloroform extracts 
of PH and CRT, n-hexane exract of GC as well as ethyl acetate extract of HL honeys. 
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4.2 MATERIALS AND METHODS 
4.2.1 Bacterial strains 
H. pylori strains used were cultured from gastric biopsy specimen obtained from patients with 
gastroduodenal pathologies attending the endoscopic unit of Livingstone Hospital, Port 
Elizabeth, South Africa. This was done after informed consent was obtained as per previously 
reported schemes (Ndip et al., 2008; Tanih et al., 2010). Confirmed isolates were stored in 
Brain Heart Infusion broth plus 20% glycerol at -80oC for subsequent bioassays. H. pylori 
ATCC (American Type Culture Collection) 43526 was used as the control.  
 
4.2.2 Preparation of honey solvent extracts 
Based on the antibacterial activity (MIC50) of the solvent extracts; the chloroform extracts of  
PH & CRT, n-hexane extract of  GC and ethyl acetate extract of  HL were the most active 
solvent extracts of the corresponding honey type. Therefore, each honey was extracted with 
the stated solvent (i.e. PH & CRT were extracted with chloroform; GC and HL were 
extracted with n-hexane and ethyl acetate respectively). This was done according to the 
method of Manyi-Loh et al. (2010). Briefly, 100 grams of crude honey was placed in a 500 
mL separating funnel, diluted with 150 mL of sterile distilled water and extracted with 150 
mL of the stated solvent for each honey type. This was performed as three successive 
extractions using 50 mL of solvent each time. 
 
The shaking time for each extraction process was 15 min, after which the mixture was 
allowed to stand to permit the solvent layer to separate. The three layers were collected, 
mixed and concentrated by evaporating the extract under reduced pressure using a rotary 
evaporator (Steroglass, Strike 202, Padua, Italy) at 40oC for n-hexane and 50oC for 
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chloroform and 60 oC for ethyl acetate respectively. Water contaminating extracts was 
removed by filtration over anhydrous sodium sulphate.  
 
4.2.3 Time-kill assay of solvent extracts 
Assay for the rate of kill of H. pylori isolates by the most active extract of each honey was 
determined in accordance with the method of Akinpelu et al. (2008) with modifications. Each 
isolate was subcultured on CBA (Oxoid, England) plates and incubated at 37oC under 
microaerophilic conditions for 2-3 days. Growth of each isolate was transferred into BHI 
broth (Oxoid, England) and incubated overnight under the same growth conditions. The 
turbidity of an 18 h old broth culture of the test isolate was standardized to contain 
approximately 1.8 x 108 cfu/mL.  
 
A 0.5mL volume of the standardized suspension was added to 4.5 mL of different 
concentrations of the extracts (1/2MIC, MIC, 2xMIC and 4xMIC). These were incubated at 
37oC under microaerophilic condition in an orbital shaker at 120rpm and the killing rate was 
determined over a period of 72hrs. Exactly 0.5mL volume of each suspension was withdrawn 
at 6h intervals and transferred to 4.5mL of BHI broth recovery medium containing 3% 
"Tween 80" to neutralize the effects of the antimicrobial compound carry-overs from the test 
isolates.  
 
The suspension was serially diluted and 100µL plated out for viable counts. The plates were 
later incubated at 37 °C for 72hrs. The control plates contained the bacterial cells without the 
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extract. The emergent bacterial colonies were counted and compared to the counts of the 
culture control. Time-kill assays were carried out in duplicate. 
 
4.3 RESULTS 
4.3.1 Time kill assay of solvent extracts 
The most active extract of each honey (i.e. chloroform extract of PH and CRT honeys, n-
hexane extract of GC honey as well as ethyl acetate extract of HL honey) was employed in 
this assay to ascertain the rate of kill of the test isolates. The results of the bactericidal 
activity of these solvent extracts over the period of 72hrs are presented on figs.4.1- 4.5. With 
the exception of chloroform extract of PH, the most potent bactericidal effect was established 
at 4xMIC (40%v/v) against the test isolates by all the honey solvent extracts at different time 
interval. Interestingly, at 1/2 MIC (5%v/v) the chloroform extract of PH honey demonstrated 
a profound bactericidal activity over a time interval of 36-72hrs. 
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  Fig. 4.1: Bactericidal activity of chloroform extract of PH honey against PE 252C 
      Fig.4.2: Bactericidal activity of chloroform extract of CRT honey against PE 252C 
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    Fig. 4.3: Bactericidal activity of ethyl acetate extract of HL honey against PE 252C 
Fig. 4.3: Bactericidal activity of n-hexane extract of GC honey against PE 252C 
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4.4 DISCUSSION 
Antimicrobial chemotherapy of H. pylori infections using the triple therapy is fraught with 
many inherent limitations such as cost, undesirable side effects, resistance and patient non-
compliance. The current rising prevalence of antibiotic-resistant H. pylori strains has led to a 
re-evaluation of the therapeutic use of natural products which are perceived as pure, and 
without side effects (Montbriand, 2004). Several studies have reported the susceptibility of H. 
pylori isolates to various brands of honeys both locally and commercially produced (Ali et 
al., 1999; Ndip et al., 2007). 
 
The bactericidal activity of the chloroform extracts of PH and CRT honeys, n-hexane extract 
of GC honey as well as ethyl acetate extract of HL honey was determined using viability 
studies. At different time intervals during cultivation, broth constituted with different 
concentrations of the solvent extracts were sampled, diluted and the total colony counts on 
the plates were enumerated in order to determine the relationship between the concentration 
of the solvent extracts, treatment time and bactericidal activity (Wang and Huang, 2005). 
Actually, the isolates were initially cultivated in the presence of the solvent extracts contained 
in the broth and subsequently, sampled, diluted and re-cultivated in the absence of the solvent 
extracts. If no colony formation was observed at that point, the extract had bactericidal 
activity (Coudon and Stratton, 1998). 
 
In this assay, it was noticed that at the time interval of 36-72hrs the test isolate was killed at a 
concentration as low as 5% v/v (1/2xMIC) by the chloroform extract of PH honey, thus it was 
the most effective bactericidal extract (Fig.4.1). At the highest concentration of 40% v/v (4x 
MIC), chloroform extract of CRT, ethyl acetate extract of HL, and n-hexane extract of GC 
presented potent bactericidal activity over the time interval of 18-72hrs and 30-72hrs 
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respectively (Fig.4.2- 4.5). This may suggest that with a further increase in extract 
concentration better results would be obtained. In addition, there was growth of bacterial cells 
at 10%v/v (MIC), showing they were inhibited as expected.  
 
4.5 CONCLUSION 
Chemical antibiotics have become obselete within a short period of time due to multidrug 
resistance presented by micro-organisms of medical importance particularly H. pylori. The 
need for an alternative antibacterial substance derived from natural products on a sustainable 
manner has become a subject of interest to scientists' the worldover. In this study, all the 
solvent extracts of the different honeys demonstrated bactericidal activity against the test 
strains at varying time intervals. 
Furthermore, due to the good inhibitory and bactericidal activity elicited by the chloroform 
extracts of PH and CRT, it is therefore needed to isolate and characterize their bioactive 
constituents in a bid to have a clear understanding on the antibacterial activity of these honey 
types. 
 
 
 
 
 
 132 
 
4.6 REFERENCES 
Akinpelu, D.A., Adegboye, M.F., Adeloye, O.A. and Okoh, A.I. (2008). Biocidal activity of 
partially purified fractions from methanolic extract of Garcinia kola (Heckel) seeds on 
bacterial isolates. Biological Research. 41:277-287. 
Ali, A.T., Chowdhury, M.N. and Al-Humayyad, M.S. (1999). Inhibitory effect of natural 
honey on Helicobacter pylori. Tropical Gastroenterology. 12: 139-143. 
Al- Somal, N.A., Coley, K.E., Molan, P.C. and Hanock, B.M. (1994). Susceptibility of 
Helicobacter pylori to the antibacterial activity of Manuka honey. Journal of the Royal 
Society of Medicine. 87: 9-12. 
Ansari, A.A. and Alexander, C. (2009). Effect of natural honey (produced by African sculata 
in Guyana) against bacteria (Pseudomonas aeruginosa, Escherichia coli and 
Staphylococcus aureus) and fungus (Candida albicans).World Journal of Diary and 
Food sciences. 4 (1):73-77. 
Beasles, I.L.P. (2001). Efficacy of Helicobacter pylori eradication therapies: a single centre 
observational study. BMC Gastroenterology. 1:1-9. 
Blaser, N.J. (1997). Not all Helicobacter pylori strains are created equal: should all be 
eliminated? Lancet. 349:1020-1022. 
Cooper, R.A., Molan, P.C., Harding, K.G. (2002). The sensitivity to honey of Gram-positive 
cocci of clinical significance isolated from wounds. Journal of Applied Microbiology. 
93: 857-863. 
Coudron, P.E. and Stratton, C.W. (1998). The bactericidal activity of clarithromycin versus 
ampicillin alone and in combination with omeprazole and/or bismuth against 
 133 
 
clarithromycin-susceptible and clarithromycin-resistant strains of Helicobacter pylori. 
Diagnostic Microbiology and Infectious Diseases. 31:39-44. 
Manyi-Loh, C.E., Clarke, A.M., Munzhelele, T., Green, E., Mkwetshana, N.F. and Ndip, 
R.N. (2010). Selected South African honeys and their extracts possess in vitro anti-
Helicobacter pylori activity. Archives of Medical Research. 41:324-331. 
Matsumoto, S., Washizuka, Y., Matsumoto, Y., Tawara, S., Ikeda, F., Yokota, Y. and Karita, 
M. (1997). Appearance of a metronidazole-resistant Helicobacter pylori strain in an 
infected-ICR-mouse model and difference in eradication of metronidazole-resistant and 
sensitive strains. Antimicrobial Agents and Chemotherapy. 41: 2602–2605. 
Molan, P.C. (2001). The potential of honey to promote oral wellness. General Dentistry. 49: 
584-589. 
Molan, P.C. and Cooper, R.A. (2000). Honey and sugar as a dressing for wounds and ulcers. 
Tropical Doctor. 30:249-251. 
Molan, P.C. (1992). The antibacterial nature of honey: the nature of the antibacterial activity. 
Bee World. 73 (1):5-28. 
Montbriand, M.J. (2004). Herbs or natural products that decrease cancer growth, part one. 
Oncology Nursing Forum. 31: 75 - 90. 
Ndip, R.N., Malange Takang, A.E., Echakachi, C.M., Malongue, A., Akoachere, J.F., Ndip, 
L.M. and Luma, H.N. (2007). In vitro antimicrobial activity of selected honeys on 
clinical isolates of Helicobacter pylori. African Health Sciences. 7: 228-231. 
Ndip, R.N., Takang, M.E.A., Ojongokpoko, A.E.J., Luma, H.N., Malongue, A., Akoachere, 
J-F.T.K., Ndip, M.L., MacMillan, M. and Weaver, T.L. (2008) Helicobacter pylori 
isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in 
 134 
 
Cameroon: Current status of antibiogram. Tropical Medicines and International 
Health.13: 848-854. 
Ochi, T., Shibata, H., Higuti, T., Kodama, K-H., Kusumi, T. and Takaishi, Y. (2005).  Anti-
Helicobacter pylori compounds from Santalum album. Journal of Natural Products. 68 
(6):819-824. 
Osman, O.F., Mansour, I.S. and El-Hakim, S. (2003). Honey compound for wound care: a 
preliminary report. Annals of Burns and Fire Disasters. 16 (3). 
Tanih, N.F., Okeleye, B.I., Naidoo, N., Clarke, A.M., Mkwetshana, N., Green, E., Ndip, L.M. 
and Ndip, R.N. (2010). Marked susceptibility of South African Helicobacter pylori 
strains to ciprofloxacin and amoxicillin: clinical implication. South African Medical 
Journal. 100:49-52. 
Wang, Y-C. and Huang, T-L.(2005). Anti-Helicobacter pylori activity of Plumbago 
zeylanica L. FEMS Immunology and Medical Microbiology. 43: 407- 412. 
Williamson, J.S. (2001). Helicobacter pylori: Current chemotherapy and new targets for drug 
design. Current Pharmaceutical Design. 7:355-392. 
Williams, E.T., Jeffrey, J., Barminas, J.T. and Toma, I. (2009). Studies on the effects of the 
honey of two floral types (Ziziphus spp. and Acelia spp.) on organisms associated with 
burn wound infections. African Journal of Pure and Applied Chemistry. 3: 98-101. 
 
 
 
 
 
 135 
 
CHAPTER FIVE 
ISOLATION AND IDENTIFICATION OF VOLATILE BIOACTIVE COMPOUNDS 
WITH ANTI- HELICOBACTER PYLORI ACTIVITY FROM HONEY 
CHLOROFORM EXTRACTS 
ABSTRACT 
The chloroform extracts of Pure Honey (PH) and Champagne Royal Train (CRT) were 
fractionated with n-hexane, chloroform and subsequently with the solvent systems, n-hexane: 
ethyl acetate: acetic acid (S1) or methanol: acetic acid: water (S2) respectively, and obtained 
several fractions that were evaluated for anti-Helicobacter pylori activity. All the fractions 
obtained with S1 solvent system demonstrated potent anti-H. pylori activity with PHF5 being 
the most active with a mean MIC50 value of 1.25mg/mL that was not significantly different 
(P> 0.05) from amoxicillin. Chemical analysis of the fractions led to the identification of 24 
volatile compounds belonging to known chemical families present in honey. From these, the 
pure compound, linalool demonstrated potent antibacterial activity at a concentration of 0.002 
and 0.0313mg/mL with inhibitory activity of 95% growth inhibition. The minimum 
bactericidal concentration (MBC) was in the range 0.0039-0.313mg/mL. Thiophene and N-
methyl-D3-aziridine were novel compounds identified in this study. They are small 
heterocyclic compounds which serve as essential intermediates in the synthesis of natural 
products and pharmaceuticals endowed with immense biomedical activities. Thus, the solvent 
extracts and fractions of these honeys could serve as potential anti-Helicobacter pylori 
regimens with therapeutic potential. 
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5.1 INTRODUCTION 
Antibiotics provide an invaluable tool for the control of microbial infections, however, micro-
organisms are gaining multi-resistance to these antibiotics after repeated treatment and this is 
a growing problem worldwide. In a bid not to select for further resistant strains, there has 
been a lot of interest in the investigation of natural products as sources of new antibacterial 
agents. Natural products and their derivatives (including antibiotics) represent more than 50% 
of all drugs in clinical use in the world (Mohapatra et al., 2010). Honey is a natural product 
with several known biological activities and has been used in folkloric medicine in different 
cultures for a long time. It may be used alone or in combination with other substances and has 
been administered both orally and topically.  
 
It is well established that honey inhibits a broad spectrum of bacterial species including 
aerobes and anaerobes, Gram positives, and Gram negatives. Its antimicrobial action could be 
bacteriostatic as well as bactericidal and may be principally useful against bacteria, which 
have developed resistance to antibiotics (Patton et al., 2006). The antimicrobial activity in 
honey has been attributed to its high sugar content, low water content, acidity and hydrogen 
peroxide.  
 
Hydrogen peroxide is known as the major contributor to the antibacterial activity, however, it 
could be destroyed when honey is diluted in the presence of catalase; as a consequence the 
antibacterial activity is reduced or eliminated. It appears that there are some honeys that 
retain their antibacterial activity even in the presence of catalase or when heated. These 
honeys therefore rely on components other than hydrogen peroxide for their potency with 
their antimicrobial compounds being postulated to be phytochemicals (Gheldof et al., 2002).  
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Besides its antimicrobial activity, honey can clear infections in a number of ways, including 
boosting the immune system, having anti-inflammatory and antioxidant activities, and via 
stimulation of cell growth (Al-jabri, 2005; Manyi-Loh et al., 2011).  
 
Despite the beneficial effects reported by researchers, there are some unpleasant attributes. 
Honey may be contaminated by bacterial spores (Bacillus and Clostridium genus), by yeast 
(Saccharomyces, Schizosaccharomyces and Torula strains) and by fungi (Penicillium and 
Mucor strains). Furthermore, altered mental status could be caused by grayanotoxin 
contaminated in honey (Gunduz et al., 2008). 
 
Depending on the sources of nectar, the composition of honey can be variable and diverse 
between bee species, locations or seasons due to foraging from different plant sources. This is 
directly related to the fact that the properties of honey depend on various factors, including 
the plant sources, climate, environment and bee species (Chanchao, 2009). Honey contains 
about 181 substances, including sugars, proteins, moisture, vitamins, minerals, 
hydroxymethylfurfural (HMF), enzymes, flavonoids, phenolic acids, volatile compounds etc. 
(Ayoub et al., 2009). Some of these substances could be extracted with organic solvents and 
have been reported to exhibit antimicrobial, antioxidant and other health beneficial 
properties. 
 
Flavonoids and phenolic molecules have been demonstrated to have direct antimicrobial 
activity against important clinical isolates including E. coli, Salmonella sp, Klebsiella sp, 
Enterobacter sp, Pseudomonas aeruginosa, Helicobacter pylori (H. pylori), methicillin-
resistant Staphylococcus aureus (MRSA) and pathogenic fungi by inhibiting nucleic acid 
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synthesis, energy metabolism or by disrupting cell membrane function (El-Gendy et al., 
2008). 
 
H. pylori is a pathogenic bacterium that persistently colonizes the gastric mucosa of human 
stomach unless treated. Currently, it is estimated that half of the world’s population harbors 
this bacterium which may occur as normal flora in some people but causes inflammation of 
gastric mucosa (gastritis) as well as duodenitis and peptic ulcers in others. If not completely 
eradicated, superficial gastric inflammation can drive a cascade of histological changes, 
resulting in an increased risk of gastric malignancies (Parsonnet, 2005).  
 
The treatment of choice for these infections entails a combination of two antibiotics, 
amoxicillin or clarithromycin and metronidazole with a proton pump inhibitor such as 
omeprazole. Eradication of H. pylori is still a challenge because of the rapidly increasing 
prevalence of multi-drug resistant strains worldwide (Fuccio et al., 2008). Tanih et al. (2010) 
in their study reported multi-drug resistance of isolates in the locality. It is therefore of great 
significance to search for alternative and complementary treatment to eradicate this pathogen 
and as well as adverse side effects encountered in the conventional treatment regimen. 
 
The anti-H. pylori activity of natural products have been documented in previous studies  
(Ndip et al., 2007; Njume et al., 2011a; Manyi-Loh et al., 2010). Recently, Manyi-Loh et al. 
(2010) reported the susceptibility of H. pylori isolates to selected South African honeys and 
their solvent extracts; the chloroform extracts of Pure honey and Champagne royal train 
exhibited bacteriostatic and bactericidal activities. As a follow up to this study, the present 
study sought to isolate, partially purify and identify the phytocomponents with anti-H. pylori 
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activity present in the chloroform extracts of Pure honey (PH) and Champagne Royal Train 
(CRT). 
 
 
5.2 MATERIALS AND METHODS 
5.2.1 Solvents and reagents 
Distilled water, vanillin reagent (Sigma-Aldrich), n-hexane, ethyl acetate, chloroform, 
concentrated sulphuric acid, acetone, dimethyl sulphoxide (DMSO), methanol and acetic acid 
used were obtained from Merck (South Africa) and linalool compound of highest purity 
(98.7%), from Dr. Ehrenstorfer GmbH, Augsburg, Germany. 
 
5.2.2 Bacterial isolates 
 Seven local strains of H. pylori isolated in the laboratory (Tanih et al., 2010) and a reference 
strain ATCC (American Type Culture Collection) 43526 were used. These strains have been 
characterized as clarithromycin and metronidazole resistant (Tanih et al., 2010). Prior to 
sensitivity testing, all H. pylori strains were revived on Columbia blood agar plates enriched 
with Skirrow’s antibiotics and 7% laked horse blood; subsequently, their identification was 
re-evaluated by morphological and biochemical characterization. The bacteria were harvested 
in Brain Heart Infusion broth supplemented with Skirrow’s antibiotics and 5% horse serum 
and incubated in a microaerophilic atmosphere (CampyGen BR0056A, Oxoid) at 37oC for 
18h. 
 
5.2.3 Preparation of honey solvent extract 
Floral sources of PH were Citrus limon and Citrus sinesis while that of CRT was the 
vineyards. Crude honeys (PH and CRT) were each extracted with chloroform solvent 
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according to the procedures that have been previously reported by Manyi-Loh et al. (2010). 
Briefly, 100 grams of crude honey was placed in a 500 mL separating funnel, diluted with 
150 mL of sterile distilled water and extracted with 150 mL of chloroform solvent. This was 
performed as three successive extractions using 50 mL of solvent each time. 
 
 The shaking time for each extraction process was 15 min, after which the mixture was 
allowed to stand to permit the solvent layer to separate. The three layers were collected; 
mixed and concentrated by evaporating the extract under reduced pressure using a rotary 
evaporator (Steroglass, Strike 202, Padua, Italy) at 50oC. Water contaminating extracts was 
removed by filtration over anhydrous sodium sulphate.  
 
5.2.4 Separation of chemical components of chloroform extracts 
Thin-layer chromatographic (TLC) technique using Silica gel plates was employed as per the 
method of Magano et al. (2008) to separate and determine the chemical compounds in the 
extracts. A concentration of 50% v/v of each extract was prepared in chloroform solvent from 
which 10µL was spotted on to TLC plates (Silica gel 60F254, Kieselgel, 20x20cm, Darmstadt, 
Germany), 1 cm from the bottom and labeled  according to the honey type ( i.e. PH and 
CRT). The spotted plates were air-dried and introduced into a TLC tank containing the 
developing solvent system. The tank was closed with a glass lid so as to have the chamber 
completely filled with the solvent vapors. Different solvent systems were tested for effective 
separation of compounds in these extracts. 
 
The two most suitable solvent systems standardized based on better separation of compounds 
were; methanol: acetic acid: water (MAAW) (10:7:3) and n-hexane: ethyl acetate: acetic acid 
(HEA) (7.8:3.5:1.25).The plates were run until the mobile phase was about 1 cm from the 
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top; subsequently they were removed from the tank and air-dried. Separated components 
were visualized under UV light at a wavelength of 254nm. To improve detection of 
compounds, the TLC chromatograms were sprayed with a mixture of vanillin-sulphuric acid 
(0.1g vanillin: 28mL methanol: 1mL concentrated sulphuric acid). The plates were heated at 
100°C for 4 min for optimal color development. Rf values of the compounds separated on the 
TLC plates were determined using the formula: ratio of the distance substance travels to the 
distance solvent travels up the plate. 
 
5.2.5 Fractionation of bioactive compounds and purification by silica gel Column 
Chromatography 
Separation and purification of compounds in the chloroform extracts by column 
chromatography was done according to the methods of Hassan et al. (2007) and Shrivastav et 
al. (2009). Slurry of Silica gel (MN Kieselgel 60, 0.063-0.2mm, Darmstadt, Germany) was 
prepared in n-hexane solvent and was used to pack two separate columns of dimension 40 x 
2.5cm (125mL); one for PH extract and the other for CRT extract. The columns were gently 
tapped to ensure uniform packing of the particles of the stationary phase as well as to 
eliminate air bubbles. They were equilibrated with n-hexane and a small quantity of the 
solvent was allowed to remain at the top of each column (about 4 cm). Each extract (6g) was 
mixed separately with Silica gel (12g) in n-hexane; they were gently mashed until the extract 
was adsorbed on the Silica gel and was allowed to dry.  
 
Each mixture in a powder form was loaded to the top of its corresponding column and eluted 
at a flow rate of 41drops /min (3mL/min), with the solvent system, n-hexane: ethyl acetate: 
acetic acid (7.8:3.5:1.25) referred to as S1, which gave a common  separation of compounds 
in both honey solvent extracts in the TLC analysis. Fractions were collected separately from 
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both columns based on the polarity of the solvent system; however, 100% n-hexane was used 
for elution of columns before employing the solvent system. Twelve (12) fractions were 
obtained from the column loaded with extract of PH (PHHex, PH F1-F11) and 9 fractions 
from the other (CRTHex, CRT F1-F8). 
 
Furthermore, a third column of the same dimension was packed with slurry of silica gel 
prepared in chloroform solvent. All the other subsequent procedures mentioned previously 
were followed strictly. The column was loaded with the chloroform extract of PH honey 
prepared in chloroform and elution was carried out firstly with chloroform solvent that was 
used for equilibration (i.e. PHCL) and later with the solvent system, methanol: acetic: water 
(10:7:3) referred to as S2, that gave the best separation of compounds in the TLC analysis of 
this extract. Four fractions were obtained (i.e. PH F1, PH F2, PH F3 &PH F4). 
 
All column fractions were concentrated by evaporation under reduced pressure using a rotary 
evaporator (Steroglass, Strike 202, Padua, Italy). The residues obtained were weighed and 
their masses were recorded as shown in Table 5.1. 
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Table 5.1: Residual weights (grams) of column fractions after evaporation at the rotary 
evaporator 
Column 
fractions  
                     Masses (grams) 
Solvent system used as mobile phase 
                        S1          S2 
         PH        CRT         PH 
Hexane      0.0018      0.0029          NA 
Chloroform       NA         NA         0.0464 
      F1       0.012     0.012         0.002 
      F2       0.015     0.023         1.063 
      F3       0.015     0.030         2.017 
      F4       0.01     0.016         0.555 
      F5       0.0227     0.030           NA 
      F6       0.0257     0.046           NA 
      F7       0.0132     0.050           NA 
      F8      0.0273     0.093           NA 
      F9      0.0356     NA           NA 
      F10      0.059     NA           NA 
      F11       0.102     NA           NA 
NA, Not applicable; S1, n-hexane: ethyl acetate: acetic acid; S2, methanol: acetic acid: water 
 
These fractions (excluding the ones with negligible masses) were tested for antibacterial 
activity by broth micro dilution method as well as for purity by TLC technique. 
 
5.2.6 Anti-Helicobacter pylori activity of column fractions and linalool 
The minimum inhibitory concentrations (MIC50) of these fractions against a local H. pylori 
clarithromycin/metronidazole resistant strain (PE93A) and H. pylori reference strain (ATCC 
43526), were evaluated following the method of Njume et al. (2011b) using broth micro 
dilution test. The column fractions obtained while eluting with S1 solvent system were each 
dissolved in 80% acetone and those obtained while eluting with S2 solvent system were 
dissolved in 10% DMSO. A stock of 20mg/mL was prepared for each fraction. Two-fold 
dilutions were prepared in 96-well-round-bottom microtitre plates (Greiner Bio-One, 
Frickenhausen, Neuburg, Germany) in BHI broth (Oxoid, England); the final concentration of 
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each fraction was 0.01-10mg/mL. Similarly, amoxicillin (0.0012 - 1.25 mg/mL), was two-
fold diluted and tested on the same plate with the column fractions as reference antimicrobial. 
Control wells were also prepared with culture medium only, culture medium with fraction 
and culture medium with bacterial isolate only. 
 
The inoculum of each strain was diluted tenfold in sterile normal saline. Twenty µL of the 
bacterial suspension (108 CFU/mL) was aliquoted into each well. The final volume in each 
well of BHI broth, fraction, and inoculum was 120µL. The absorbencies were read using an 
ELISA microtitre plate reader (Model 680, S/N 19138, Biorad, Japan) adjusted at 620nm. 
The micro plates were sealed and incubated at 37oC under microaerophilic conditions for 2-
3days, agitated and the absorbencies were again read at the same wavelength. The 
absorbencies were compared to the values obtained before incubation to detect any increase 
or decrease in bacterial growth. The lowest concentration of the extract resulting in inhibition 
of bacterial growth by 50% was taken as MIC50.  
 
Subsequently, the very active fractions were subjected to GC-MS analysis to determine their 
chemical composition.  In order to trace and identify the active ingredient(s),  the effect of 
linalool was tested (found in the most active fraction, PH F5) against an increased number of 
H. pylori drug resistant strains (Bergonzelli et al., 2003). The MIC assay was carried out as 
previously described above and a stock concentration of linalool, 1mg/mL prepared in 80% 
acetone or 100% ethanol (EtOH) was employed. Stock concentrations of amoxicillin, 
0.0000019-0.002mg/mL were equally used as the positive control.  MIC was the lowest 
concentration of linalool or amoxicillin that resulted in inhibition of bacterial growth by 95%. 
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The minimum bactericidal concentration (MBC) was evaluated by the method of Vila et al. 
(2010). Following MIC, 2μL of each sample was spread on Columbia blood agar plates and 
incubated at 37oC under microaerophilic conditions (CampyGen, Oxoid, England) for 72hrs. 
Plates were checked for bacterial growth and MBC was recorded as the lowest concentration 
at which no colony of H. pylori was formed on the plates. Each experiment was done in 
triplicate and amoxicillin was used as the positive control. 
 
5.2.7 Test for purity of column fractions 
To test for purity of these fractions (i.e. to check if the fractions were composed of a single 
compound), a secondary TLC analysis was carried out employing the solvent systems, n-
hexane; ethyl acetate: acetic acid (7.8: 3.5: 1.25) or methanol: acetic acid: water (10:7:3) 
depending on the fraction. The developed chromatograms were viewed under UV light at 
254nm before and after staining with vanillin-sulphuric acid (0.1g vanillin: 28mL methanol: 
1mL concentrated sulphuric acid). Rf values of the spots were calculated. 
 
5.2.8 Analysis of the chemical components of honey solvent extracts by Gas 
chromatography-Mass spectrometry (GC-MS) 
Considering the mean MIC50 values of the fractions, PHF5, PHF6, PHF10, PHF11, CRTF2, 
CRTF3, CRTF5 obtained with S1 solvent system and PHF2, PHF3 and PHF4 obtained with 
S2 solvent system were subjected to GC-MS analysis to determine their volatile constituents.  
The GC-MS analyses of the volatiles were carried out using Hewlett-Packard HP 5973 mass 
spectrometer interfaced with an HP-6890 gas chromatograph with an HP5 column (Wiley, 
New York, USA). The following conditions were used: initial temperature 70 oC, maximum 
temperature 325 oC, equilibration time 3 min, ramp 4 oC/min, final temperature 240 oC; inlet: 
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split less, initial temperature 220 oC, pressure 8.27 psi, purge flow 30 ml/min, purge time 
0.20 min, gas type helium; column: capillary, 30 m × 0.25 mm i.d., film thickness 0.25 μm, 
initial flow 0.7 ml/min, average velocity 32 cm/s; MS: EI method at 70 eV. The components 
of the oils were identified by matching their mass spectra and retention indices with those of 
the Wiley 275 library (Wiley, New York) in the computer library and literature (Joulain et al., 
2001; Abd El-Moaty, 2010).The yield of each component was calculated per kg of the honey 
material, while the percentage composition was calculated from the summation of the peak 
areas of the total oil composition.  
 
5.2.9 Statistical analysis 
ANOVAs –one-way test was carried out while employing MINITAB (version 14.0 for 
Windows) to determine if there was any statistically significant difference in comparing the 
MIC50 values of the column fractions to each other as well as to the positive control, 
amoxicillin. Equally, the MIC95 and MBC values of linalool were compared to amoxicillin. 
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5.3 RESULTS 
5.3.1 Thin layer chromatography analysis of chloroform extracts 
Of all the solvent systems employed as mobile phases, the best separation of compounds (8 
bands) was obtained from the chloroform extract of PH honey with the solvent system, 
methanol: acetic acid: water (10:7:3) while for CRT there was smearing throughout the plate 
(no distinct bands). Furthermore, a common separation of three bands was achieved with the 
solvent system, n-hexane: ethyl acetate: acetic acid (7.8:3.5:1.25) for both chloroform 
extracts. Calculated Rf values for the separated bands are shown in Table 5.2. 
 
Table 5.2:  Rf values of separated bands presented by the different honey chloroform extracts 
resolved by thin layer chromatography (TLC) with different solvent systems 
 
Solvent systems used as 
mobile phase 
                            Rf values  
Chloroform extract of PH Chloroform extract of CRT 
10-methanol                  0.81                 Smear 
7-acetic acid                 0.69   
                 0.67   
                 0.64   
                  0.48  
                  0.35  
                  0.31  
                  0.16  
7.8-n-hexane                  0.83                 0.83  
3.5-ethyl acetate                  0.7                  0.68 
1.25-acetic acid                  0.6                  0.53 
Rf, retention factor 
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5.3.2 Evaluation of MIC50 of column fractions 
The anti-Helicobacter pylori effect of the column fractions in the MIC50 assay is shown in 
table 5.3. All the fractions (PHF1-F11, CRTF1-F8 and PHCL, PHF2-F4) demonstrated 
antibacterial activity with MIC50 values that ranged from 1.25 - 10mg/mL. Considering the 
different eluting solvent system, PH F5 and PH F11 were the most potent of all the fractions, 
although there was no significant difference (P > 0.05) in the activity of all fractions (except 
PHF1 &CRTF1) compared to the positive control, amoxicillin (MIC50 range 0.625-
1.25mg/mL). Of the four fractions obtained with the solvent system S2, PH F3 presented the 
best activity with MIC50 values in the range 2.5-5mg/mL even though there was significant 
difference in activity of all the fractions (P< 0.05) compared to amoxicillin. 
 
 
 
 149 
 
Table 5.3: Anti-Helicobacter pylori effect of column fractions recorded as MIC50  
H. pylori 
isolates 
                                          MIC50   values of all the chromatographic fractions and positive control 
                                                                      Solvent system used as mobile phase AMOX 
                                                                                                           S1                 S2 
                        Chloroform extract of PH           Chloroform extract of  CRT Chloroform extract of   PH      
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F1 F2 F3 F4 F5 F6 F7 F8 PHCL F2 F3 F4 
PE 93A 5 5 5 5 1.25 1.25 2.5 5 5 5 1.25 5 5 5 ND 2.5 ND ND 10 ND 5 2.5 5 0.625 
ATCC43526 10 5 2.5 2.5 1.25 5 10 2.5 2.5 1.25 2.5 10 2.5 5 5 5 2.5 2.5 2.5 10 5 5 5 1.25 
Mean 7.5 5 3.75 3.75 1.25 3.13 6.25 3.75 3.75 3.13 1.88 7.5 3.75 5 ND 3.75 ND ND 6.25 ND 5 3.75 5 0.94 
ND, Not determined. 
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5.3.3 Test for purity of fractions 
The secondary TLC analysis of all the fractions obtained with S1 solvent system showed that 
they were partially purified since the chromatograms presented more than one band 
(Figs.5.1a-c). The chromatogram of the four fractions obtained with the S2 solvent system 
presented a single broad black band in each fraction. However, the volatile constituents in the 
fractions were identified by GC-MS analysis. 
 
 
 
 
 
                        
   
 
 
 
 
 
 
 
 
 
Fig.5.1a: TLC chromatograms of PH fractions employing S1 solvent system (HEA) 
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 Fig. 5.1b: TLC chromatograms of CRT fractions employing S1 solvent system (HEA) 
 
                        
 
 
 
 
 
 
 
 
 
Fig. 5.1c: TLC chromatograms of PH fractions employing S2 solvent system (MAAW) 
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5.3.4 Analysis of the chemical components of honey solvent extracts by Gas 
chromatography-Mass spectrometry (GC-MS). 
The volatile compounds which are part of the chloroform extract were analyzed by GC-MS, 
and the data are reported in table 5.4. A total of 24 volatile compounds were identified in all 
the column fractions. However, 15 volatile compounds were obtained with the S1 solvent 
system and 12 with the S2 solvent system. The PH F5 fraction contained the highest number 
of volatiles. 
 
Compounds identified included hydrocarbons, alcohol, aldehydes, ketones, acids, terpenes 
and its derivatives, benzene derivatives, furan and pyran derivatives, thiophene, N-methyl-D3 
aziridine and propanenitrile. 
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Table 5.4: Volatile compounds identified in column fractions of chloroform extracts of PH and CRT honeys 
Compounds               Area percentage (%) of volatile compounds in each column fraction 
                                    Solvent system used as mobile phase 
                                                  S1 S2 
PH5 PH6 PH10 PH11 CRT2 CRT3 CRT5 PH2 PH3 PH4 
Hexane 89.4 96.8 - 7.75 54.83 17.86 4.56 - - 19.98 
Octane 0.37 - - - - - - - - - 
Cyclohexane 5.97 - - - - - - - - - 
Acetic acid - - 29.26 11.12 - - - 80.63 70.57 54.73 
Hexadecanoic acid 0.45 - - - - - - - - - 
Butanal - - - - - - 5.55 - - 23.66 
Succinaldehyde - - - - - - - - 0.62 - 
3-cyclohexene-1-acetaldehyde 0.15 - - - - - - - - - 
2-propanone - - - - - - - 6.47 10.06 1.63 
2,5-furandione - - - - - - - 1.72 2.21 - 
Toluene 1.52 1.69 - - - - - - - - 
1,2-dimethyl benzene 0.26 0.23 - - - - - - - - 
1,3-dimethyl benzene 1.36 1.29 - - - - - - - - 
1,3-benzenediamine - - - - - - - - 0.95 - 
Epoxy linalool 0.20 - - - - - - - - - 
Linalool 0.17 - - - - - - - - - 
1-octen-7-methylocta-1,3(z),5(E)-triene 0.13 - - - - - - - - - 
Furfuryl alcohol - - - - - - - 3.02 4.22 - 
1-Butanol - - - - - - - 1.42 - - 
Methanol - - - - 45.17 - - - - - 
2,3-dihydro-3,5-dihydroxy-6-methyl-4H-
pyran-4-one 
- - - - - - - 6.75 9.2 - 
N-methyl-D3-Arizidine - - - - - - - - 0.43 - 
Thiophene - - - - - - - - 1.74 - 
Methanamine hydrochloride - - 70.74 81.13 - 82.14 89.89 - - - 
-,Not Found; S1, n-hexane; ethyl acetate; acetic acid (7.8:3.5:1.25): S2, methanol; acetic acid: water (10:7:3)
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5.3.5 Evaluation of the anti-Helicobacter pylori activity of linalool pure compound 
(Standard) 
MIC95 and MBC values of linalool compound in the different diluents against the test isolates 
were as observed in table 5.5. The compound demonstrated inhibitory activity at a concentration 
ranging from 0.002 - 0.0313mg/mL while the bactericidal activity against the isolates was in the 
range 0.0039 - 0.0313m/mL. Amoxicillin recorded MIC95 and MBC values that ranged from 
0.00000195 - 0.002mg/mL. 
 
Table 5.5: Antibacterial activity of Linalool (mg/mL), a volatile compound characterized from 
the chloroform extract of Pure honey 
 
H. pylori isolates Minimum Inhibitory Concentration (MIC) Minimum Bactericidal Concentration 
(MBC) 
Linalool Amoxicillin Linalool Amoxicillin 
PE 93A 0.0156 0.001 0.0156 0.001 
PE 219C 0.002 0.00000195 0.0039 0.00000195 
PE252C 0.0156 0.002 0.0156 0.002 
PE 308C 0.0156 0.002 0.0156 0.0005 
PE369A 0.0078 0.000125 0.0313 0.000125 
PE435A 0.0156 0.0005 0.0156 0.0005 
PE436A 0.0313 0.0005 0.0313 0.0005 
ATCC 43526 0.0156 0.0005 0.0156 0.0005 
Mean  0.0149  0.0117  
 
 
 155 
 
 
5.4 DISCUSSION 
Investigations into honey varieties as alternative sources of antimicrobials have become more 
common over the past few years, due to the increased rate of development of antibiotic resistant 
organisms. Honey has been recognized for their many pharmacological activities such as its anti-
oxidant, antimicrobial, anti-inflammatory, anticancer and immune modulating properties 
(Manyi-Loh et al., 2011). 
 
In the TLC analysis of chloroform extracts of PH and CRT honeys, the main aim was to 
ascertain the number and chromatographic behavior of the compounds present in each extract. Of 
all the solvent systems employed MAAW (10:7:3) resolved the mixture of chloroform extract of 
PH into eight distinct bands while a common separation of three bands was obtained for both 
extracts with HEA (7.8:3.5:1.25); thus suggesting the presence of compounds since an earlier 
report by Stalikas (2007) stated that non-polar compounds such as hydrocarbons, waxes, fatty 
acids, alkaloids and essential oils present in natural products could be extracted with chloroform.  
 
The fractions obtained from column chromatographic separation of both extracts were subjected 
to MIC assay to determine their anti-H. pylori effect. All the fractions demonstrated anti-H. 
pylori activity with MIC50 values that ranged from 1.25 - 10mg/mL and was dependent on the 
fractions, test strain and the solvent system. This inhibitory activity may be an indication that 
different compounds with antibacterial activity might have been among the phytochemical 
constituents of the chloroform extracts of these honeys. This result is in conformity with the 
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work of Nwodo et al. (2010) that equally reported good antibacterial activity of their column 
fractions.  
 
Although, there was no significant difference (P>0.05) in activity between fractions obtained 
with the S1 solvent system compared to the positive control, amoxicillin, fractions PHF5 
(1.25mg/mL) and PHF11 (1.88mg/mL) were potent in activity and close to the control. This may 
indicate that the compounds in these fractions might demonstrate antibacterial activity seeming 
that of amoxicillin.  
 
On the other hand, there was a significant difference (P<0.05) in activity of all the fractions 
obtained with the S2 solvent system compared to the positive control, amoxicillin. PHF3 
(3.75mg/mL) in this category demonstrated the best antibacterial activity. This may imply that 
the compounds present in PHF3 could be of better antimicrobial potential than those in the other 
fractions. Taking into consideration the MIC50 values of PH obtained with the different solvent 
system, it is important to note that better antimicrobial activity was generally elicited by fractions 
obtained with the S1 solvent system. This may suggest that the solubility or polarity of this 
solvent system allowed many bioactive compounds to dissolve in it and thus became eluted 
(Doughari, 2006). 
 
Volatile compounds in honey have been reported to have their origins, in general terms, in 
different chemical families such as: alcohols, hydrocarbons, ketones, aldehydes, acids, esters, 
terpenes, norisoprenoids, benzene compounds and their derivatives, furan and pyran derivatives 
(Cuevas-Glory et al., 2007). In this study, a total of 24 volatile compounds were identified in the 
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chloroform extracts of two different honeys with different solvent systems. They were classified 
into the following; hydrocarbons (3), alcohols (2), aldehydes (3), ketones (2), benzene 
derivatives (4), acids (2), terpenes and its derivatives (3), furan and pyran compounds (2), 
sulphur compound (1), aziridine derivative (1) and nitrile compound (1).  
 
Our most potent fractions PHF3, PHF5 and PHF11 contained these compounds. 
Cyclohydrocarbons, benzene derivatives, fatty acids and terpenes have been reported to exhibit 
antimicrobial activity; due to their lipophilicity they present hydrophobic interaction with lipid 
bilayer membrane of the organism thus affect the functioning of the membrane and membrane 
embedded proteins (Trombetta et al., 2005). Consequently, the membrane becomes more 
permeable, and other compounds present in the fraction could make their way into the bacterium 
(Nalina and Rahim, 2007). 
 
Meotti et al. (2003) in their study reported that furan derivatives are a new important class of 
pharmacological agents which have been found to show antibacterial, antiviral, antifungal and 
antioxidant activities. In addition, linalool as well as pyran derivatives obtained by maillard 
reaction have been reported to possess anti-oxidant activity. The presence of these compounds in 
this study may suggest that their antioxidant property could be of prime importance during 
respiratory burst in H. pylori-induced mucosal damage, scavenging for free reactive oxygen 
species (Li et al., 2001). 
 
Furthermore, linalool and epoxy linalool are monoterpenes which are the dominant group of 
chemical components found in nearly all essential oils of many types of plants and flowers. 
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However, since there were many compounds in each of these fractions, there may be need to 
determine the active compound (s). Identification of the active component(s) in the most active 
fraction should allow better standardization of the antimicrobial activity. In this light, the anti-H. 
pylori effect of linalool compound was tested. Though its relative abundance in the PH fraction 
is low, it has previously been identified as a characteristic marker of citrus floral source and has a 
wide range of activity spectrum (Bergonzelli et al., 2003; Castro-Várquez et al., 2007).  
 
Taking into consideration, that essential oil and many of its components have limited solubility 
in aqueous medium which in turn could affect its activity (Bergonzelli et al., 2003; Kubo et al., 
2001); linalool compound was diluted in both 80% acetone and 98 % EtOH and its activity tested 
against an increased number of H. pylori drug resistant strains by broth microdilution. The MIC95 
ranges for the compound in 80% acetone and EtOH were 0.002 - 0.0313mg/ml and 0.0078-
0.0313mg/mL respectively; which were not significantly different (P > 0.05) from the MIC 95 
values of the positive control (0.00000195 - 0.002mg/mL). This may suggest that the therapeutic 
potential of linalool compound against H. pylori strains is highly comparable to the classical 
antibiotic, amoxicillin (Manyi-Loh et al., 2010). Consequently, 80%  acetone could be used  to 
substitute  EtOH that has often been reported as the solvent of choice for diluting  most essential 
oils and their components  prior to susceptibility testing (Bergonzelli et al., 2003; Koutsoudaki et 
al., 2005). 
 
As observed in table 5.5, all the isolates were sensitive to linalool although, the strain PE 219C 
was the most sensitive been inhibited and killed at concentrations as low as 0.002mg/mL and 
0.0039mg/mL respectively. The test compound demonstrated significant anti-H. pylori activity 
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that ranged from 0.002 - 0.313mg/mL (mean MIC 0.0149mg/mL or 14.9μg/mL). This is in 
contrast with the finding of Vila et al. (2010) who reported a MIC value of 62.5μg/mL against 
their H. pylori isolates. The MBC values of the test compound were between 0.0039 and 
0.0313mg/mL. With the exception of strains PE 219C and PE369A, MIC95 and MBC values 
were markedly the same for the other six strains, indicating that the activity of the compound at 
the said concentrations was bactericidal. This result is in line with the finding of Kubo et al. 
(2001).  
 
The most remarkable finding was the presence of thiophene and aziridine compounds in the 
chloroform extract of PH. They are heterocyclic compounds whose nuclei represent a very 
important field in drug discovery, since they serve as precursors for the synthesis of 
natural/synthetic biological products endowed with cosmic pharmacological activities including 
antiviral, antibacterial, antifungal, anticonvulsant, antiasthmatic, anti-inflammation and 
antiprotozoal effects (Ismail et al., 2009; Sivadas et al., 2011). In the continuous venture to 
develop potent and novel antimicrobial agents, small molecules have traditionally been a reliable 
source consequently; heterocycles (thiophenes and aziridines) would remain an active area of 
investigation (Sivadas et al., 2011). 
 
However, only four volatile compounds were identified in the fractions obtained from CRT 
honey. As shown in table 5.4, we can safely conclude that the non-peroxide anti-H. pylori 
activity of this honey may not be due to volatile compounds but to other phytochemicals as the 
phytochemicals in honey could be grouped into carbohydrates, phenolic compounds (flavonoids 
& non-flavonoid phenolic compounds) and volatiles (Kaškonienė and Venskutonis, 2010). 
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5.5 CONCLUSION  
The anti-H. pylori activity of chloroform extract of Pure honey could be attributed to a 
combination of several compounds even though not all have been identified in this study. It 
would be essential to examine each antibacterial component of the extract separately, and in 
combination to ascertain whether they act alone or synergistically.  Nevertheless, the chloroform 
extract of PH and CRT could serve as a natural source of lead molecules that could be further 
harnessed for the development of novel anti-H. pylori agents that may greatly contribute to the 
efficient control of this bacterial pathogen which is ubiquitous  and whose mode of  transmission 
is still elusive. Further studies are needed to identify the non-volatile phytochemicals in the 
extracts with anti-H. pylori activity as well as to test for toxicity. 
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CHAPTER SIX 
GENERAL DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 GENERAL DISCUSSION 
The traditional use and anecdotal evidence of “Iqhilika” (Mead) (obtained from fermentation of 
honey in the presence of yeast and water) as medicine in the treatment of stomach ailments by 
the Xhosa people in the Eastern Cape Province provided the basis for suggesting that honey and 
its solvent extracts may be useful for specific medical conditions.  
 
In this study, all the honeys at concentrations between 10% and 75% v/v had inhibitory effect on 
the growth of H. pylori strains. The antibacterial activity was evidenced by the observation of 
clear zones of inhibition around each well with diameter which ranged from 11.0-16 mm. Based 
on zone diameter of sensitive strain ≥ 14mm, the percentage of susceptible strains recorded was 
between 46.7 and 73.3. These results are consistent with earlier reports on the antibacterial 
activity of locally produced honeys in different parts of the world (Omojasola, 2002; Wilkinson 
and Cavanagh, 2005). However, the results were variable; with three honeys (PH, CB and GC) 
being most active at 75%  v/v concentration while the others (CRT, HL and HH) were most 
active at 50% v/v concentration. 
 
In crude and unprocessed honey, its osmolarity, acidity and hydrogen peroxide content are 
factors exhibiting antibacterial activity (Mandal and Mandal, 2011). Hydrogen peroxide has been 
reported as the leading antibacterial factor in honey and its concentration is determined by the 
relative levels of glucose oxidase, synthesized by the bee and catalase originating from flower 
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pollen (Weston, 2000). Therefore, there is the possibility that peroxide activity could vary from 
one local honey sample to another. On dilution of some types of honeys, glucose oxidase 
generates hydrogen peroxide at levels lethal to the bacteria (Halawani and Shohayeb, 2011). This 
may suggest that hydrogen peroxide could be responsible for the variation in antibacterial 
activity of the tested honeys obtained from different floral sources since they were diluted. 
 
Nonetheless, no statistical significant difference was found in the antibacterial activity among the 
honey varieties; consequently PH, GC, CRT and HL honeys with better antibacterial activity 
were extracted with four organic solvents viz. n-hexane, diethyl ether, chloroform and ethyl 
acetate. All the extracts of each honey demonstrated potent antibacterial activity with no 
significant difference in activity between the extracts even though variations occurred in 
diameter of zones of inhibition as well as in the percentage of susceptible isolates. This may 
suggest that honey contains copious amounts of bioactive molecules which could easily 
solubilise in organic solvents (Maji et al., 2010).  
 
Subsequently, in the assay to determine the MIC at 50%  bacterial growth inhibition of the two 
most active extracts of each honey, it was revealed that the most active extract of each honey 
were; n-hexane  extract of GC, ethyl acetate extract of HL, and chloroform extracts of PH and 
CRT respectively. These results indicate that the inhibitory effect was dependent on the choice of 
solvent (Aljadi and Yusoff, 2003) as well as the honey type since phytoconstituents in honey 
varies with geographical location and climate (Kaškonienė and Venskutonis, 2010). 
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Furthermore, the above-mentioned active extracts of each honey were subjected to time kill 
assay in order to determine their bactericidal activity against H. pylori over 72 hour’s time 
interval. Interestingly, at 1/2 MIC (5%v/v) the chloroform extract of PH honey demonstrated a 
profound bactericidal activity over a time interval of 36-72hrs. For the other solvent extracts, the 
most potent bactericidal effect was established at 4xMIC (40%v/v) against the test isolates at 
different time interval. This may suggest that with a further increase in extract concentration 
better results would be obtained. In addition, there was growth of bacterial cells at 10%v/v 
(MIC), showing they were inhibited as expected. 
 
In the TLC assay  to separate the  compounds present in the chloroform extracts of PH and CRT, 
eight bands were found on the TLC  plate spotted with extract of PH and developed with the 
solvent system, methanol: acetic acid: water (MAAW) (10:7:3). A common separation of three 
bands was observed on the TLC plate spotted with both PH and CRT extracts and developed 
with the solvent system, n-hexane: ethyl acetate: acetic acid (HEA) (7.8: 3.5:1.25). The presence 
of these bands creates awareness of the possibility of phytochemical compounds in the extracts. 
The chemical constituents may be therapeutically active or inactive.The ones which are active 
are called active constituents and the inactive ones are known as inert chemical constituents 
(Kamba and Hassan, 2010). Notwithstanding, the active constituents have the advantage of being 
combined with the inactive compounds whose complementary effect gives honey as a whole 
safety and efficiency much superior to that of its isolated and pure active compounds (Shariff, 
2001). 
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Upon separation and purification of chloroform extracts with two solvent system; HEA (S1) and 
MAAW (S2) by column chromatographic technique, numerous fractions were obtained 
designated PHF1-PHF11 and PHCL, PHF1-PHF4 (S2)  for PH extract and CRTF1-CRT F8 for 
CRT extract and evaluated for antibacterial activity. Overall, the best antibacterial activity was 
demonstrated by fractions PHF5 and PHF11 with MIC values of 1.25mg/mL and 1.88 mg/mL 
respectively, which were not significantly different from the positive control, amoxicillin 
(0.94mg/mL). This may suggest that the therapeutic potential of these fractions could be 
comparable to that of the classical antibiotic (Ndip et al., 2007). Albeit, fractions PHF6, PHF10, 
PHF2, PHF3, PHF4 and CRTF2, CRTF3 and CRTF5 demonstrated slight antibacterial activity. 
It is believed that further fractionation and purification of such fractions might still result in the 
isolation of useful bioactive substances (Njume et al., 2011). 
 
Accordingly, it is worth significance to identify the chemical constituents present in these active 
fractions. Knowledge about the chemical constituents may lead to the discovery of the true 
relevance of the folkloric medicinal use of these honeys in different cultures for the treatment of 
multiple ailments. The volatile compounds identified in the active fractions of both solvent 
extracts belonged to known chemical groups; alcohols, acids, ketones, aldehydes, benzene 
derivatives, terpenes and its derivatives, furan and pyran derivatives previously identified in 
honey by several other authors (Castro-Várquez et al., 2006; De la Fluente et al., 2007). 
However, only four volatile compounds, methanol, hexane, butanal and methanamine 
hydrochloride were identified in the chloroform extract of CRT. 
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Of novelty was the presence of thiophene and N3-methyl-D3-aziridine compounds, essential 
precursors used for the synthesis of natural products and pharmaceuticals endowed with vital 
biomedical properties, in the chloroform extract of PH. However, some volatile compounds 
might have been lost during solvent evaporation of the extracts and fractions as well as not being 
detected by the GC column due to masking effect of the solvent (Cuevas-Glory et al., 2007). 
Furthermore, some of the above mentioned compounds have been reported for their known 
antimicrobial, anti-inflammatory and anti-oxidant properties against other pathogenic bacteria 
(Paduch et al., 2007; Manilal et al., 2009).  
 
In order to trace the compound responsible for the antibacterial activity of the most active 
fractions, the anti-H. pylori activity of linalool pure compound was evaluated against an 
increased number of H. pylori strains. Linalool demonstrated potent antibacterial activity with 
MIC at 95% bacterial growth inhibition that ranged from 0.002 to 0.0313mg/mL and bactericidal 
activity between 0.0039 and 0.0313mg/mL. These results are in agreement with previous studies 
on the significant anti-H. pylori activity of linalool compound (Koutsoudaki et al., 2004; Vila et 
al., 2009). 
 
Even though, the other known antimicrobial compounds identified in the solvent extract of PH, 
have not been evaluated singly for anti-H. pylori activity, the possibility of synergistic and or 
antagonistic actions amongst these compounds should not be overlooked.Therefore, Pure honey 
could provide a natural, economic  and readily available source of bioactive compounds. In 
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addition, these volatile compounds might not only be employed for the synthesis of novel drugs 
or therapeutic agents but could also aid in the determination of botanical origin of these honeys 
as well as the aroma profile (Castro-Várquez et al., 2006). 
 
6.2 GENERAL CONCLUSIONS 
From the results of this study, it is worth mentioning that; 
1) Crude honeys such as PH, CB, GC, CRT, HH &HL obtained in South Africa 
demonstrated potent anti-H. pylori activity at concentrations ≥ 10%v/v. 
2) Solvent extracts of these honeys (PH, GC, CRT, HL) equally exhibited profound 
bacteriostatic and bactericidal activities, with the chloroform extracts of PH and CRT 
being the most efficient; thus presenting chloroform solvent as the best medium for the 
extraction of active pharmacological agents in honey. 
3) Upon fractionation and purification of the chemical compounds present in the chloroform 
extract of PH, numerous volatile compounds were identified belonging to known 
chemical groups such as alcohols, aldehydes, acids, ketones,  terpenes, benzene and their 
derivatives, furan and pyran derivatives which have been previously identified by several 
authors (Castro-Várquez et al., 2007; Barra et al., 2010). 
4) Two novel compounds; thiophene and N-methyl-D3-aziridine were identified in this 
extract and could be part of the antibacterial components responsible for the potent 
antibacterial activity revealed by the chloroform extract of PH. 
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5) Linalool compound elicited profound bacteriostatic and bactericidal actions against H. 
pylori isolates thus could be one of those compounds responsible for the antibacterial 
activity of the chloroform extract of PH. 
6) Above all, these honeys in their crude form could become part of a dietary-based 
approach for the management of H. pylori infections in asymptomatic individuals, 
especially since they are of natural origin and pose a low risk for the development of 
resistance or could be used as adjunct in conventional triple therapy regimen to alleviate 
the unpleasant side effects of the drugs. 
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6.3 RECOMMENDATIONS 
1) Further studies should be done to identify other compounds with anti-H. pylori 
activity among the volatile components identified in the chloroform extract of PH. 
2) Further purification of the active column fractions obtained from chloroform extract 
of PH should be conducted in order to obtain pure forms of the compounds. 
3) Subsequently, toxicological analysis of the compounds becomes necessary. 
4) The non volatile constituents (flavonoid and non-flavonoid phenolic compounds) in 
the active column fractions obtained from the chloroform extracts of PH and CRT 
need to be investigated by High Performance Liquid chromatography and the anti-H. 
pylori activity of the identified compounds evaluated. 
5) The mechanisms of action of the identified active compounds need to be evaluated in 
vivo. 
6) The crude honeys and their solvent extracts should be tested against other pathogenic 
organisms including Gram positive and negative bacterial species as well as fungi 
species in a bid to evaluate their broad spectrum activity. 
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